Anti-PD-1 monoclonal antibody as well as derivative and application thereof
Patent Information
- Application Number
- CN202380031078.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-02
- Filing Date
- 2023-03-31
- Publication Date
- 2024-11-12
AI Technical Summary
Existing anti-PD-1 monoclonal antibodies have low objective response rates in the treatment of various tumors, mainly due to the lack of immune cells in tumor tissues and/or the presence of a high proportion of immunosuppressive cells, resulting in poor response to immunotherapy.
Developed a new anti-PD-1 antibody and its derivatives, which have excellent affinity and biological activity, can specifically bind to PD-1, block the combination of PD-1 and PD-L1, enhance immune cell activity, and By combining the fusion protein with the TGF-β/TGF-βR pathway inhibitor, T cell immune suppression is relieved and the anti-tumor activity is improved.
It significantly improves the objective response rate and survival time of tumor patients, provides better clinical efficacy, and enhances immune response and anti-tumor effects.
Smart Images

Figure CN118946587A_ABST
Abstract
Description
Anti-PD-1 monoclonal antibodies and their derivatives and uses Technical Field
[0001] The present invention relates to the field of biomedicine or biopharmaceutical technology, and more specifically to an anti-PD-1 monoclonal antibody and its derivatives and uses. Background Art
[0002] Programmed cell death protein-1 (PD-1, also known as CD279) is normally expressed on activated lymphocytes and is further upregulated on tumor-infiltrating lymphocytes. PD-1 can inhibit T cell overactivation and proliferation by binding to its ligands PD-L1 and PD-L2, which are highly expressed on tumor cells and antigen-presenting cells. This negatively regulates the immune system and mediates tumor immune escape.
[0003] Currently, several anti-PD-1 monoclonal antibodies have been approved for the treatment of various tumors (such as classical Hodgkin's lymphoma, squamous or non-squamous NSCLC, hepatocellular carcinoma, nasopharyngeal carcinoma, urothelial carcinoma, esophageal squamous cell carcinoma, melanoma, etc.). However, the approved indications for anti-PD-1 monoclonal antibodies are mostly concentrated in certain tumor types that are sensitive to immunotherapy, and the objective response rate of monotherapy for most tumor types is low (most are less than 30%). One of the important reasons may be that there are few immune cells infiltrating in tumor tissues and / or a high proportion of immunosuppressive cells (such as Treg, MDSC), as well as the participation of other immunosuppressive pathways.
[0004] Therefore, it is urgent and necessary to develop anti-PD-1 antibodies or their derivatives with better clinical efficacy, which will provide more medication options for patients with cancer, infection and other diseases.
[0005] Summary of the Invention
[0006] After in-depth research and creative work, the inventors have obtained new anti-PD-1 antibodies and their derivatives. The inventors surprisingly discovered that the anti-PD-1 antibodies and their derivatives of the present invention have good affinity and biological activity, and have anti-tumor potential. The following invention is provided:
[0007] Antibodies of the present invention
[0008] Therefore, in one aspect, the present invention provides an antibody or antigen-binding fragment thereof that can specifically bind to PD-1, wherein the antibody or antigen-binding fragment thereof comprises:
[0009] A heavy chain variable region (VH) comprising the following three complementarity determining regions (CDRs): VH CDR1 of SEQ ID NO: 7 or 13, VH CDR2 of SEQ ID NO: 8, and VH CDR3 of SEQ ID NO: 9; and / or,
[0010] A light chain variable region (VL) comprising the following three complementarity determining regions (CDRs): VL CDR1 of SEQ ID NO: 10, VL CDR2 of SEQ ID NO: 11 or 14, and VL CDR3 of SEQ ID NO: 12.
[0011] In certain embodiments, the antibody or antigen-binding fragment thereof comprises: three CDRs contained in the VH set forth in SEQ ID NO: 1, 3, or 5, and / or three CDRs contained in the VL set forth in SEQ ID NO: 2, 4, or 6. In certain embodiments, the CDRs are identified by the Kabat numbering system, the Chothia numbering system, or the IMGT numbering system.
[0012] In certain embodiments, the antibody or antigen-binding fragment thereof comprises:
[0013] (1) the three CDRs contained in the VH set forth in SEQ ID NO: 1, and / or the three CDRs contained in the VL set forth in SEQ ID NO: 2;
[0014] (2) the three CDRs contained in the VH set forth in SEQ ID NO: 3, and / or the three CDRs contained in the VL set forth in SEQ ID NO: 4; or
[0015] (3) The three CDRs contained in VH shown in SEQ ID NO: 5, and / or the three CDRs contained in VL shown in SEQ ID NO: 6.
[0016] In certain embodiments, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region (VH) comprising the following three complementarity determining regions (CDRs): VH CDR1 of SEQ ID NO: 7, VH CDR2 of SEQ ID NO: 8, and VH CDR3 of SEQ ID NO: 9; and / or a light chain variable region (VL) comprising the following three complementarity determining regions (CDRs): VL CDR1 of SEQ ID NO: 10, VL CDR2 of SEQ ID NO: 11, and VL CDR3 of SEQ ID NO: 12.
[0017] In certain embodiments, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region (VH) comprising the following three complementarity determining regions (CDRs): VH CDR1 with a sequence of SEQ ID NO: 13, VH CDR2 with a sequence of SEQ ID NO: 8, and VH CDR3 with a sequence of SEQ ID NO: 9; and / or a light chain variable region (VL) comprising the following three complementarity determining regions (CDRs): VL CDR1 with a sequence of SEQ ID NO: 10, VL CDR2 with a sequence of SEQ ID NO: 14, and VL CDR3 with a sequence of SEQ ID NO: 12.
[0018] In certain embodiments, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region (VH) comprising the sequence shown in SEQ ID NO: 1, 3 or 5 or a variant thereof; and / or a light chain variable region (VL) comprising the sequence shown in SEQ ID NO: 2, 4 or 6 or a variant thereof.
[0019] In certain embodiments, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region (VH) comprising the sequence shown in SEQ ID NO: 1 or 3 or a variant thereof; and / or a light chain variable region (VL) comprising the sequence shown in SEQ ID NO: 2 or 4 or a variant thereof.
[0020] In certain embodiments, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region (VH) comprising the sequence shown in SEQ ID NO: 1 or a variant thereof; and / or a light chain variable region (VL) comprising the sequence shown in SEQ ID NO: 2 or a variant thereof.
[0021] In certain embodiments, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region (VH) comprising the sequence shown in SEQ ID NO: 3 or a variant thereof; and / or a light chain variable region (VL) comprising the sequence shown in SEQ ID NO: 4 or a variant thereof.
[0022] In certain embodiments, the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region (VH) comprising the sequence shown in SEQ ID NO: 5 or a variant thereof; and / or a light chain variable region (VL) comprising the sequence shown in SEQ ID NO: 6 or a variant thereof.
[0023] The variants described in any of the above embodiments have one or more amino acid substitutions, deletions or additions (e.g., 1, 2, 3, 4 or 5 amino acid substitutions, deletions or additions) compared to the sequence from which they are derived, or a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity; preferably, the substitutions are conservative substitutions.
[0024] In certain embodiments, the antibody or antigen-binding fragment thereof comprises:
[0025] (1) a VH comprising the sequence shown in SEQ ID NO: 1 and a VL comprising the sequence shown in SEQ ID NO: 2;
[0026] (2) a VH comprising the sequence shown in SEQ ID NO: 3 and a VL comprising the sequence shown in SEQ ID NO: 4; or,
[0027] (3) VH comprising the sequence shown in SEQ ID NO: 5 and VL comprising the sequence shown in SEQ ID NO: 6.
[0028] In certain embodiments, the antibody or antigen-binding fragment thereof in any of the above embodiments may further comprise a constant region sequence derived from a mammalian (eg, mouse or human) immunoglobulin.
[0029] In certain embodiments, the heavy chain of the antibody or antigen-binding fragment thereof in any of the above embodiments comprises a heavy chain constant region derived from a mouse or human immunoglobulin (e.g., IgG1, IgG2, IgG3, or IgG4). In certain embodiments, the light chain of the antibody or antigen-binding fragment thereof in any of the above embodiments comprises a light chain constant region derived from a mouse or human immunoglobulin (e.g., κ or λ).
[0030] In certain embodiments, the heavy chain constant region is an IgG heavy chain constant region, such as an IgG1, IgG2, IgG3, or IgG4 heavy chain constant region.
[0031] In certain embodiments, the heavy chain constant region (CH) has the same or substantially the same effector function as a wild-type heavy chain constant region sequence.
[0032] In certain embodiments, the heavy chain constant region (CH) may comprise one or more amino acid mutations or chemical modifications to alter one or more of the following properties of the antibodies of the invention: Fc receptor binding, antibody glycosylation, the number of cysteine residues, effector cell function, or complement function, among others. Functional changes can be produced by replacing at least one amino acid residue in the antibody constant region with a different residue or chemically modifying it, for example, by altering the affinity of the antibody for an effector ligand (such as FcR or complement C1q), thereby altering effector function (e.g., reducing or enhancing it). The Fc region of an antibody mediates several important effector functions, such as ADCC, phagocytosis, CDC, and the like.
[0033] In certain embodiments, the heavy chain constant region (CH) has reduced or abolished ADCC activity, for example, comprising a LALA mutation (L234A, L235A).
[0034] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain constant region (CH) as shown in SEQ ID NO:15 and / or a light chain constant region (CL) as shown in SEQ ID NO:16.
[0035] In certain embodiments, the antigen-binding fragment of any of the above embodiments can be selected from Fab, Fab', (Fab')2, Fv, disulfide-linked Fv, scFv, and diabody.
[0036] In certain embodiments, the antibody of any of the above embodiments is a chimeric antibody, a humanized antibody, a bispecific antibody, or a multispecific antibody.
[0037] scFv
[0038] In certain embodiments, the antigen-binding fragment in any of the above embodiments is an scFv. It is known in the art that the stability of the scFv structure can be enhanced by forming interchain disulfide bonds. Therefore, in certain embodiments, the scFv comprises a disulfide bond. Methods for introducing disulfide bonds in scFv are well known to those skilled in the art, for example, by introducing cysteine (C) into the VH and VL of the scFv, respectively. In certain embodiments, the VH and VL of the first antigen-binding domain each comprise a residue located in the FR region that is mutated to cysteine (C), such that the scFv formed by the VH and VL may comprise a disulfide bond. In certain embodiments, a residue in the FR2 region of the VH of the first antigen-binding domain and a residue in the FR4 region of the VL are mutated to cysteine (C).
[0039] In certain embodiments, the scFv preferably comprises the VH set forth in SEQ ID NO: 3 and the VL set forth in SEQ ID NO: 4, or comprises the VH set forth in SEQ ID NO: 5 and the VL set forth in SEQ ID NO: 6. In such embodiments, the scFv comprises an interchain disulfide bond.
[0040] In certain embodiments, the scFv has a structure as shown in VH-L-VL or VL-L-VH, wherein L is a peptide linker. In certain embodiments, L is a peptide linker comprising one or more glycine (G) and / or one or more serine (S) and / or one or more alanine (A), for example, a flexible peptide comprising (G4S)n or (G4A)n, where n = 1, 2, 3, or 4. In certain exemplary embodiments, L is (G4S)4.
[0041] In certain embodiments, the scFv may further comprise another biologically active polypeptide in its N-segment and / or C-segment to extend its half-life, forming a polypeptide construct. In certain embodiments, the other biologically active polypeptide is an immunoglobulin Fc domain.
[0042] In certain embodiments, the immunoglobulin Fc domain is optionally connected to the N-terminus or C-terminus (e.g., N-terminus) of the scFv via a peptide linker. In certain embodiments, the peptide linker comprises one or more glycines (G) and / or one or more serines (S) and / or one or more alanines (A), such as a flexible peptide comprising (G4S)n or (G4A)n, where n=1, 2, 3, or 4. In certain exemplary embodiments, the peptide linker is (G4S)2 or (G4A)2.
[0043] In certain embodiments, the immunoglobulin Fc domain is the Fc domain of IgG (eg, the Fc domain of IgG1).
[0044] In certain embodiments, the immunoglobulin Fc domain comprises the sequence shown in SEQ ID NO:22.
[0045] In certain exemplary embodiments, the scFv comprises the sequence shown in SEQ ID NO: 23 or 24.
[0046] In certain embodiments, the antibodies or antigen-binding fragments thereof of the present invention have at least one of the following biological functions:
[0047] (1) Specific recognition / binding to PD-1 (especially human PD-1);
[0048] (2) blocking the binding of PD-1 to PD-L1, or inhibiting and / or blocking intracellular signaling mediated by PD-1 binding to PD-L1;
[0049] (3) increasing the activity of immune cells (such as T cells) in vitro and in vivo, such as increasing the secretion level of effector cytokines (e.g., IL-2, IFN-γ, etc.), proliferation activity, expression level of activation markers (e.g., CD25, CD69, etc.), and / or cell killing activity;
[0050] (4) enhancing immune responses (such as T cell-mediated immune responses) in vitro and in vivo;
[0051] (5) Preventing and / or treating tumors or infections in subjects.
[0052] Herein, the antibodies or antigen-binding fragments thereof of the present invention may include variants that differ from the antibody or antigen-binding fragment thereof from which they are derived only in conservative substitutions of one or more (e.g., conservative substitutions of up to 20, up to 15, up to 10, or up to 5 amino acids) amino acid residues, or have at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the antibody or antigen-binding fragment thereof from which they are derived, and substantially retain the above-mentioned biological functions of the antibody or antigen-binding fragment thereof from which they are derived.
[0053] Derivatized antibodies
[0054] The antibodies or antigen-binding fragments thereof of the present invention may be derivatized, for example, linked to another molecule (e.g., another polypeptide or protein). Generally, the derivatization (e.g., labeling) of an antibody or its antigen-binding fragment does not adversely affect its binding to PD-1 (particularly human PD-1). Therefore, the antibodies or antigen-binding fragments thereof of the present invention are also intended to include such derivatized forms. For example, the antibodies or antigen-binding fragments thereof of the present invention may be functionally linked (by chemical coupling, gene fusion, non-covalent linkage or other means) to one or more other molecular groups, such as another antibody (e.g., to form a bispecific antibody), a detection reagent, a pharmaceutical agent, and / or a protein or polypeptide (e.g., avidin or a polyhistidine tag) that can mediate binding of the antibody or antigen-binding fragment to another molecule. In addition, the antibodies or antigen-binding fragments thereof of the present invention may also be derivatized with chemical groups, such as polyethylene glycol (PEG), a methyl or ethyl group, or a glycosyl group. These groups can be used to improve the biological properties of antibodies, such as increasing serum half-life.
[0055] Therefore, in certain embodiments, the antibodies or antigen-binding fragments thereof of the present invention are labeled. In certain embodiments, the antibodies or antigen-binding fragments thereof of the present invention are labeled with a detectable marker, such as an enzyme, a radionuclide, a fluorescent dye, a luminescent substance (such as a chemiluminescent substance), or biotin. The detectable marker of the present invention can be any substance that can be detected by fluorescent, spectral, photochemical, biochemical, immunological, electrical, optical, or chemical means. Such labels are well known in the art, and examples thereof include, but are not limited to, enzymes (e.g., horseradish peroxidase, alkaline phosphatase, β-galactosidase, urease, glucose oxidase, etc.), radionuclides (e.g., 3 H. 125 I. 35 S. 14 C or 32 P), fluorescent dyes (e.g., fluorescein isothiocyanate (FITC), fluorescein, tetramethylrhodamine isothiocyanate (TRITC), phycoerythrin (PE), Texas Red, rhodamine, quantum dots or cyanine dye derivatives (e.g., Cy7, Alexa 750)), luminescent substances (e.g., chemiluminescent substances such as acridinium ester compounds), magnetic beads (e.g., ), calorimetric labels such as colloidal gold or colored glass or plastic (e.g., polystyrene, polypropylene, latex, etc.) beads, and biotin for binding to avidin (e.g., streptavidin) modified with the above-mentioned labels. In certain embodiments, such labels can be suitable for immunological detection (e.g., enzyme-linked immunosorbent assay, radioimmunoassay, fluorescent immunoassay, chemiluminescent immunoassay, etc.). In certain embodiments, the detectable labels described above can be linked to the antibodies or antigen-binding fragments thereof of the present invention via linkers of varying lengths to reduce potential steric hindrance.
[0056] In another aspect, the present invention also provides a conjugate comprising the antibody or antigen-binding fragment thereof of the present invention and a therapeutic agent linked to the antibody or antigen-binding fragment thereof.
[0057] In certain embodiments, the conjugate is an antibody-drug conjugate (ADC). In certain preferred embodiments, the therapeutic agent is selected from a cytotoxin or a radioisotope. In the present invention, non-limiting examples of suitable therapeutic agents include antimetabolites, alkylating agents, DNA minor groove binders, DNA intercalators, DNA cross-linking agents, histone deacetylase inhibitors, nuclear export inhibitors, proteasome inhibitors, topoisomerase I or II inhibitors, heat shock protein inhibitors, tyrosine kinase inhibitors, antibiotics and antimitotic agents.
[0058] In certain embodiments, the antibodies or antigen-binding fragments thereof of the present invention are optionally conjugated to the therapeutic agent via a linker. In certain embodiments, the antibodies or antigen-binding fragments thereof of the present invention are conjugated to the therapeutic agent via a cleavable linker (e.g., a peptide linker, a disulfide linker, or a hydrazone linker).
[0059] Fusion protein
[0060] As mentioned above, due to the small number of immune cells infiltrating in tumor tissues and / or the presence of a high proportion of immunosuppressive cells (such as Treg, MDSC), as well as the involvement of other immunosuppressive pathways, the objective response rate of anti-PD-1 antibody monotherapy for some tumor types is low.
[0061] To solve the above problems, the inventors of the present application, based on obtaining a PD-1 antibody with excellent performance, further provide a fusion protein to provide better anti-tumor activity.
[0062] In another aspect, the present invention also provides a fusion protein comprising the antibody or antigen-binding fragment thereof of the present invention and another biologically active polypeptide fused thereto.
[0063] In certain embodiments, the additional biologically active polypeptide is connected to the antibody or antigen-binding fragment thereof via a peptide linker. In certain embodiments, the peptide linker comprises one or more glycines (G) and / or one or more serines (S) and / or one or more alanines (A), such as a flexible peptide comprising (G4S)n or (G4A)n, where n=1, 2, 3, or 4. In certain exemplary embodiments, the peptide linker is (G4A)4G.
[0064] In certain embodiments, the additional biologically active polypeptide is an immunomodulatory agent.
[0065] In certain embodiments, the immunomodulator is a TGF-β / TGF-βR pathway inhibitor.
[0066] Transforming growth factor-β (TGF-β) is a class of cytokines with multiple biological activities, secreted by tumor cells or immune cells, mainly including TGF-β1, TGF-β2, and TGF-β3. The TGF-β signaling pathway is an important factor in the formation of an immunosuppressive tumor microenvironment. The concentration of TGF-β in serum is negatively correlated with clinical outcomes. The main mechanisms include: (1) inhibiting the proliferation and activation of CD8+ T cells; (2) inhibiting the killing activity of NK cells; and (3) inducing the production of immunosuppressive cells such as M2 macrophages, MDSCs, and Tregs. In addition, TGF-β can also promote tumor cell invasion by inducing fibrosis and angiogenesis. Neutralizing TGF-β in the tumor microenvironment helps reduce tumor invasion, inhibit tumor growth, and restore vascular normalization. At the same time, blocking TGF-β signaling may enhance the clinical efficacy of immune checkpoint inhibitors.
[0067] Based on this, the inventors of the present application developed a fusion protein comprising the PD-1 antibody of the present invention and a TGF-β / TGF-βR pathway inhibitor, which simultaneously and specifically binds to PD-1 and TGF-β and blocks the PD-L1 / PD-1 and TGF-β / TGF-βR pathways, thereby relieving T cell immunosuppression, better exerting anti-tumor activity, improving the objective response rate of tumor patients, and prolonging the survival of tumor patients.
[0068] In certain embodiments, the immunomodulator is a TGF-βRII extracellular domain. In certain embodiments, the TGF-βRII extracellular domain comprises the sequence shown in SEQ ID NO:19.
[0069] In certain embodiments, the fusion protein comprises: a first peptide chain comprising the light chain of the antibody or antigen-binding fragment thereof; and a second peptide chain comprising the heavy chain of the antibody or antigen-binding fragment thereof and the additional biologically active polypeptide.
[0070] In certain embodiments, the first peptide chain comprises the sequence shown in SEQ ID NO: 17, and / or the second peptide chain comprises the sequence shown in SEQ ID NO: 18.
[0071] polypeptide constructs
[0072] When using the antigen-binding fragment of the present invention, in order to increase its half-life, it can be linked to a biologically active polypeptide capable of increasing half-life to form a construct. Therefore, the present invention also provides such a polypeptide construct.
[0073] In another aspect, the present invention also provides a polypeptide construct comprising the antibody or antigen-binding fragment thereof of the present invention and an immunoglobulin Fc domain.
[0074] In certain embodiments, the antibody or antigen-binding fragment thereof is an antigen-binding fragment. In certain embodiments, the antigen-binding fragment is Fab, Fab', (Fab')2, Fv, disulfide-linked Fv, scFv, or diabody.
[0075] As used herein, the Fc domain, also referred to as the Fc region, refers to the portion of the heavy chain constant region comprising CH2 and CH3. In some embodiments, the Fc domain comprises a hinge, CH2, and CH3. When the Fc domain comprises a hinge, the hinge mediates dimerization between two Fc-containing polypeptides. The Fc domain can be of any antibody heavy chain constant region isotype. In some embodiments, the Fc domain is IgG1, IgG2, IgG3, or IgG4.
[0076] In certain embodiments, the Fc domain included in the polypeptide construct of the present invention is a native Fc region, which comprises an amino acid sequence consistent with the amino acid sequence of the Fc region found in nature. For example, the Fc domain can be a native sequence human IgG1 Fc region, a native sequence human IgG2 Fc region, a native sequence human IgG3 Fc region, or a native sequence human IgG4 Fc region. A native Fc region may have effector functions. Exemplary "effector functions" include binding to Fc receptors; Clq binding and complement-dependent cytotoxicity (CDC); antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; downregulation of cell surface receptors (e.g., B cell receptors); and B cell activation, etc. Functional changes can be produced by replacing at least one amino acid residue in the native Fc region with a different residue or chemical modification, for example, changing the affinity of the antibody for effector ligands (such as FcR or complement Clq), thereby changing the effector function (e.g., reducing or enhancing).
[0077] Therefore, in certain embodiments, the Fc domain comprised by the polypeptide construct of the present invention may also be a variant Fc region, which may comprise one or more (e.g., 1-10, such as 1-5) amino acid mutations or chemical modifications compared to a native Fc region to alter one or more of the following properties of the antibody of the present invention: Fc receptor binding, antibody glycosylation, the number of cysteine residues, effector cell function, or complement function, etc.
[0078] In certain embodiments, the Fc domain has reduced or abolished ADCC activity, for example, comprising a LALA mutation (L234A, L235A).
[0079] In certain embodiments, the immunoglobulin Fc domain is the Fc domain of IgG (eg, the Fc domain of IgG1).
[0080] In certain exemplary embodiments, the immunoglobulin Fc domain comprises the sequence shown in SEQ ID NO:22.
[0081] In certain embodiments, the immunoglobulin Fc domain is optionally connected to the antibody or antigen-binding fragment thereof (e.g., N-terminus and / or C-terminus) via a peptide linker. In certain embodiments, the peptide linker comprises one or more glycines (G) and / or one or more serines (S) and / or one or more alanines (A), such as a flexible peptide comprising (G4S)n or (G4A)n, where n=1, 2, 3, or 4. In certain exemplary embodiments, the peptide linker is (G4S)2 or (G4A)2.
[0082] In certain embodiments, the polypeptide construct comprises the scFv described above and an immunoglobulin Fc domain. In certain embodiments, the immunoglobulin Fc domain is connected to the N-terminus of the scFv.
[0083] In certain exemplary embodiments, the polypeptide construct comprises the sequence shown in SEQ ID NO: 23 or 24.
[0084] Preparation of antibodies, fusion proteins, and peptide constructs
[0085] The antibodies of the present invention can be prepared by various methods known in the art, such as by genetic engineering recombinant technology. For example, DNA molecules encoding the heavy and light chain genes of the antibodies of the present invention can be obtained by chemical synthesis or PCR amplification. The resulting DNA molecules are inserted into expression vectors and then transfected into host cells. The transfected host cells are then cultured under specific conditions to express the antibodies of the present invention.
[0086] The antigen-binding fragments of the present invention can be obtained by hydrolyzing intact antibody molecules (see Morimoto et al., J. Biochem. Biophys. Methods 24:107-117 (1992) and Brennan et al., Science 229:81 (1985)). Alternatively, these antigen-binding fragments can be produced directly from recombinant host cells (reviewed in Hudson, Curr. Opin. Immunol. 11:548-557 (1999); Little et al., Immunol. Today, 21:364-370 (2000)). For example, Fab' fragments can be obtained directly from host cells; Fab' fragments can be chemically coupled to form F(ab')2 fragments (Carter et al., Bio / Technology, 10:163-167 (1992)). In addition, Fv, Fab, or F(ab')2 fragments can also be directly isolated from recombinant host cell culture fluid. Other techniques for preparing such antigen-binding fragments are well known to those of ordinary skill in the art.
[0087] Therefore, in another aspect, the present invention provides a kind of isolated nucleic acid molecule, it comprises the nucleotide sequence of encoding antibody of the present invention or its Fab, or its heavy chain variable region and / or light chain variable region.In certain embodiments, the isolated nucleic acid molecule encodes antibody of the present invention or its Fab, or its heavy chain variable region and / or light chain variable region.
[0088] In another aspect, the present invention provides a vector (eg, a cloning vector or an expression vector) comprising the isolated nucleic acid molecule described above.
[0089] In another aspect, the present invention provides a host cell comprising the isolated nucleic acid molecule or vector. Such host cells include, but are not limited to, prokaryotic cells such as Escherichia coli cells, and eukaryotic cells such as yeast cells, insect cells, plant cells, and animal cells (such as mammalian cells, such as mouse cells, human cells, etc.).
[0090] In another aspect, a method for preparing the antibody or antigen-binding fragment thereof of the present invention is provided, which comprises culturing the above-mentioned host cell under conditions allowing expression of the antibody or antigen-binding fragment thereof, and recovering the antibody or antigen-binding fragment thereof from the cultured host cell culture.
[0091] In another aspect, the present invention also provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a fusion protein of the present invention. In certain embodiments, the isolated nucleic acid molecule encodes a fusion protein of the present invention. The present invention also provides a vector (e.g., a cloning vector or an expression vector) comprising the isolated nucleic acid molecule. The present invention also provides a host cell comprising the isolated nucleic acid molecule or vector. The present invention also provides a method for preparing the fusion protein of the present invention, comprising culturing the host cell under conditions that allow expression of the fusion protein, and recovering the fusion protein from the cultured host cell culture.
[0092] In another aspect, the present invention also provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide construct of the present invention. In certain embodiments, the isolated nucleic acid molecule encodes a polypeptide construct of the present invention. The present invention also provides a vector (e.g., a cloning vector or an expression vector) comprising the isolated nucleic acid molecule. The present invention also provides a host cell comprising the isolated nucleic acid molecule or vector. The present invention also provides a method for preparing a polypeptide construct of the present invention, comprising culturing the host cell under conditions that allow expression of the polypeptide construct, and recovering the polypeptide construct from the cultured host cell culture.
[0093] Composition
[0094] In another aspect, the present invention also provides a composition comprising: (1) an antibody or antigen-binding fragment thereof or a polypeptide construct of the present invention; and (2) an immunomodulator.
[0095] In certain embodiments, the immunomodulator is a TGF-β / TGF-βR pathway inhibitor, such as the TGF-βRII extracellular domain.
[0096] In certain embodiments, the composition comprises: an antibody of the invention or an antigen-binding fragment thereof (e.g., a VH comprising the sequence shown in SEQ ID NO: 1 and a VL comprising the sequence shown in SEQ ID NO: 2), and a TGF-βRII extracellular domain.
[0097] In certain embodiments, the agents described in (1) and (2) are provided as separate components or as components of the same composition. Thus, the agents described in (1) and (2) can be administered simultaneously, separately, or sequentially.
[0098] Pharmaceutical compositions and therapeutic applications
[0099] The antibodies or antigen-binding fragments thereof of the present invention can be used in vitro or in vivo to inhibit and / or block intracellular signal transduction mediated by PD-1 binding to PD-L1, increase immune cell activity, enhance immune response, and prevent and / or treat tumors or infections.
[0100] Therefore, in another aspect, the present invention provides a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, fusion protein, polypeptide construct or conjugate, or composition of the present invention, and a pharmaceutically acceptable carrier and / or excipient.
[0101] In certain embodiments, the pharmaceutical composition includes a fusion protein comprising an antibody or antigen-binding fragment thereof of the present invention and a TGF-β / TGF-βR pathway inhibitor (e.g., the extracellular domain of TGF-βRII), which simultaneously and specifically binds to PD-1 and TGF-β and blocks the PD-L1 / PD-1 and TGF-β / TGF-βR pathways, thereby relieving T cell immunosuppression, better exerting anti-tumor activity, improving the objective response rate of tumor patients, and prolonging the survival of tumor patients.
[0102] In certain embodiments, the pharmaceutical composition may further comprise an additional pharmaceutically active agent.
[0103] In certain embodiments, the additional pharmaceutically active agent is a drug with anti-tumor activity, such as another immune checkpoint inhibitor, an oncolytic virus, a chemotherapeutic agent, an anti-angiogenic drug, an antimetabolite drug, a targeted tumor drug, an immunostimulant, and the like.
[0104] In certain embodiments, the additional pharmaceutically active agent is a drug used to treat infection, such as an antiviral agent, an antifungal agent, an antibacterial agent, an immunostimulant, and the like.
[0105] In certain embodiments, in the pharmaceutical composition, the antibody or antigen-binding fragment thereof, fusion protein, polypeptide construct or conjugate, or composition of the present invention and the additional pharmaceutically active agent are provided as separate components or as components of the same composition. Thus, the antibody or antigen-binding fragment thereof, fusion protein, polypeptide construct or conjugate, or composition of the present invention and the additional pharmaceutically active agent can be administered simultaneously, separately or sequentially.
[0106] In certain exemplary embodiments, the medicament comprises a sterile injectable liquid (e.g., an aqueous or non-aqueous suspension or solution). In certain exemplary embodiments, such sterile injectable liquid is selected from water for injection (WFI), bacteriostatic water for injection (BWFI), sodium chloride solution (e.g., 0.9% (w / v) NaCl), glucose solution (e.g., 5% glucose), a solution containing a surfactant (e.g., 0.01% polysorbate 20), a pH buffered solution (e.g., phosphate buffered solution), Ringer's solution, and any combination thereof.
[0107] In another aspect, the present invention relates to the use of the antibody or antigen-binding fragment thereof, fusion protein, polypeptide construct or conjugate, or composition of the present invention in the preparation of a medicament for:
[0108] (1) increasing the activity of immune cells (e.g., T cells) in vitro or in a subject (e.g., human);
[0109] (2) enhancing an immune response (e.g., a T cell-mediated immune response) in a subject (e.g., a human);
[0110] (3) treating a tumor in a subject (e.g., a human); or
[0111] (4) Treating an infection in a subject (e.g., a human).
[0112] In certain embodiments, the drug includes a fusion protein comprising an antibody or antigen-binding fragment thereof of the present invention and a TGF-β / TGF-βR pathway inhibitor (e.g., the extracellular domain of TGF-βRII), which simultaneously and specifically binds to PD-1 and TGF-β and blocks the PD-L1 / PD-1 and TGF-β / TGF-βR pathways, thereby relieving T cell immunosuppression, better exerting anti-tumor activity, improving the objective response rate of tumor patients, and prolonging the survival of tumor patients.
[0113] In another aspect, the present invention provides a method for increasing immune cell activity and / or enhancing an immune response in a subject, the method comprising administering to a subject in need thereof an effective amount of the antibody (or antigen-binding fragment thereof), fusion protein, polypeptide construct, conjugate, composition or pharmaceutical composition of the present invention.
[0114] In certain embodiments, the immune response is a T cell-mediated immune response.
[0115] In certain embodiments, the method is for preventing and / or treating a tumor. In such embodiments, the subject has a tumor.
[0116] In certain embodiments, the method is for preventing and / or treating an infection. In such embodiments, the subject has an infection.
[0117] In certain embodiments, the immune cell is a T cell, such as a cytotoxic T cell (CTL), an antigen-specific T cell, or a tumor infiltrating T cell (TIL-T). In certain exemplary embodiments, the immune cell is a tumor infiltrating lymphocyte, such as a tumor infiltrating T cell.
[0118] In certain embodiments, a fusion protein comprising an antibody or antigen-binding fragment thereof of the present invention and a TGF-β / TGF-βR pathway inhibitor (e.g., the extracellular domain of TGF-βRII) is administered to the subject, which simultaneously and specifically binds to PD-1 and TGF-β and blocks the PD-L1 / PD-1 and TGF-β / TGF-βR pathways, thereby relieving T cell immunosuppression, better exerting anti-tumor activity, improving the objective response rate of tumor patients, and prolonging the survival of tumor patients.
[0119] In another aspect, the present invention provides a method for preventing and / or treating tumors in a subject (e.g., a human), comprising administering to a subject in need thereof an effective amount of an antibody (or antigen-binding fragment thereof), fusion protein, polypeptide construct, conjugate, composition or pharmaceutical composition of the present invention.
[0120] In certain embodiments, a fusion protein comprising an antibody or antigen-binding fragment thereof of the present invention and a TGF-β / TGF-βR pathway inhibitor (e.g., the extracellular domain of TGF-βRII) is administered to the subject, which simultaneously and specifically binds to PD-1 and TGF-β and blocks the PD-L1 / PD-1 and TGF-β / TGF-βR pathways, thereby relieving T cell immunosuppression, better exerting anti-tumor activity, improving the objective response rate of tumor patients, and prolonging the survival of tumor patients.
[0121] In certain embodiments, the antibodies (or antigen-binding fragments thereof), fusion proteins, polypeptide constructs or conjugates, or compositions of the present invention are used in combination with another drug having anti-tumor activity. Such another drug having anti-tumor activity can be administered before, simultaneously with, or after administration of the antibody (or antigen-binding fragment thereof), fusion protein, polypeptide construct or conjugate, or composition.
[0122] In certain embodiments, the antibodies (or antigen-binding fragments thereof), fusion proteins, polypeptide constructs, conjugates, compositions or pharmaceutical compositions of the present invention are administered in combination with additional therapies. Such additional therapies can be any therapy known for tumors, such as surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy, hormone therapy, gene therapy or palliative care. Such additional therapies can be administered before, simultaneously with or after the administration of the antibodies (or antigen-binding fragments thereof), fusion proteins, polypeptide constructs, conjugates, compositions or pharmaceutical compositions of the present invention.
[0123] In another aspect, the present invention provides a method for preventing and / or treating infection in a subject (e.g., a human), comprising administering to a subject in need thereof an effective amount of an antibody (or antigen-binding fragment thereof), fusion protein, polypeptide construct, conjugate, composition or pharmaceutical composition of the present invention.
[0124] In certain embodiments, the antibodies (or antigen-binding fragments thereof), fusion proteins, polypeptide constructs or conjugates or compositions of the present invention are used in combination with another drug for treating an infection. Such another drug for treating an infection can be administered before, simultaneously with, or after administration of the antibody (or antigen-binding fragment thereof), fusion protein, polypeptide construct or conjugate or composition.
[0125] In certain embodiments of the uses and methods described above, the tumor is a tumor with microsatellite instability-high (MSI-H) and / or mismatch repair deficiency (dMMR).
[0126] According to the MSI detection classification standard established by the National Cancer Institute (NCI) of the United States (Boland CR, et al. Cancer Res. 1998 Nov 15; 58(22): 5248-57.), for the five microsatellite standard sites, BAT26, BAT25, D2S123, D5S346, and D17S250, compared with normal tissue, if the tumor tissue contains two or more unstable sites, it is judged as microsatellite high instability (MSI-H), that is, mismatch repair function deficiency (dMMR); if less than two sites are unstable or no site is unstable, it is judged as microsatellite low instability (MSI-L) or microsatellite stable (MSS), that is, mismatch repair function is intact (pMMR).
[0127] Methods for detecting microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR) are known to those skilled in the art. For example, PCR or next-generation sequencing can be used to detect changes in the length of the five standard microsatellite loci in tumor tissue. If two or more loci are unstable, the diagnosis is MSI-H. Alternatively, immunohistochemistry (IHC) can be used to detect the expression of MLH1, MSH2, MSH6, and PSM2 in tumor tissue. If all four proteins are positive, the diagnosis is pMMR; if any one of the proteins is negative, the diagnosis is dMMR.
[0128] In certain embodiments of the uses and methods described above, the tumor is a solid tumor, such as melanoma (e.g., metastatic malignant melanoma), breast cancer, renal cancer (e.g., clear cell carcinoma), prostate cancer, bladder cancer, pancreatic cancer, lung cancer (e.g., non-small cell lung cancer), colon cancer, esophageal cancer, head and neck squamous cell carcinoma, liver cancer, ovarian cancer, cervical cancer, thyroid cancer, glioblastoma, and glioma.
[0129] In certain embodiments of the uses and methods described above, the tumor is a blood tumor, such as a lymphoma or leukemia. In certain embodiments, the lymphoma is Hodgkin's lymphoma or non-Hodgkin's lymphoma. In certain embodiments, the non-Hodgkin's lymphoma is one or more of peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma, NK / T-cell lymphoma (nasal type) with Epstein-Barr virus positivity, and B-cell non-Hodgkin's lymphoma.
[0130] In certain embodiments of the uses and methods described above, the infection refers to any infection caused by any pathogenic microorganisms such as viruses, bacteria, fungi, parasites, etc. In certain embodiments, the infection is selected from viral infection, bacterial infection, fungal infection and parasitic infection.
[0131] In certain embodiments of the uses and methods described above, the subject is a mammal, such as a human.
[0132] The antibodies or antigen-binding fragments thereof, fusion proteins, polypeptide constructs, conjugates, compositions, and pharmaceutical compositions of the present invention can be formulated into any dosage form known in the medical field, for example, tablets, pills, suspensions, emulsions, solutions, gels, capsules, powders, granules, elixirs, lozenges, suppositories, injections (including injections, sterile powders for injection, and concentrated solutions for injection), inhalants, sprays, and the like. The preferred dosage form depends on the intended route of administration and therapeutic use. The pharmaceutical compositions of the present invention should be sterile and stable under production and storage conditions. A preferred dosage form is an injection. Such an injection can be a sterile injectable solution. For example, a sterile injectable solution can be prepared by the following method: incorporating the recombinant protein of the present invention in a suitable solvent at the required dose, and optionally, simultaneously incorporating other desired ingredients (including but not limited to, pH adjusters, surfactants, adjuvants, ionic strength enhancers, isotonic agents, preservatives, diluents, or any combination thereof), followed by filtration and sterilization. In addition, the sterile injectable solution can be prepared as a sterile lyophilized powder (e.g., by vacuum drying or freeze drying) for easy storage and use. Such sterile lyophilized powder can be dispersed in a suitable carrier before use, such as water for injection (WFI), bacteriostatic water for injection (BWFI), sodium chloride solution (e.g., 0.9% (w / v) NaCl), glucose solution (e.g., 5% glucose), a solution containing a surfactant (e.g., 0.01% polysorbate 20), a pH buffer solution (e.g., phosphate buffer solution), Ringer's solution, and any combination thereof.
[0133] In addition, the antibodies or antigen-binding fragments thereof, fusion proteins, polypeptide constructs, and conjugates of the present invention can be presented in pharmaceutical compositions in the form of unit dosages for ease of administration.
[0134] Antibody of the present invention or its antigen-binding fragment, fusion protein, polypeptide construct, conjugate, composition, pharmaceutical composition can be used by any suitable method known in the art, including but not limited to, oral, oral, sublingual, eyeball, local, parenteral, rectal, intrathecal, intracytoplasmic reticulum groove, inguinal, intravesical, local (such as, powder, ointment or drops), or nasal route. But, for many therapeutic uses, preferred route of administration / mode is parenteral administration (such as intravenous injection or push injection, subcutaneous injection, intraperitoneal injection, intramuscular injection). Technicians should understand that route of administration and / or mode will change according to intended purpose. In a preferred embodiment, antibody of the present invention or its antigen-binding fragment, fusion protein, polypeptide construct, conjugate, composition, pharmaceutical composition is given by intravenous injection or push injection.
[0135] The pharmaceutical compositions of the present invention may include a "therapeutically effective amount" or a "prophylactically effective amount" of the antibodies or antigen-binding fragments thereof, fusion proteins, polypeptide constructs, conjugates, or compositions of the present invention. A "prophylactically effective amount" refers to an amount sufficient to prevent, prevent, or delay the onset of a disease. A "therapeutically effective amount" refers to an amount sufficient to cure or at least partially prevent the disease and its complications in a patient already suffering from the disease. The therapeutically effective amount of the antibodies or antigen-binding fragments thereof, fusion proteins, polypeptide constructs or conjugates, or compositions of the present invention may vary depending on the severity of the disease to be treated, the overall state of the patient's own immune system, the patient's general condition such as age, weight, and sex, the mode of administration of the drug, and other treatments administered concurrently, etc.
[0136] Kits and detection applications
[0137] The antibodies or antigen-binding fragments thereof of the present invention can specifically bind to PD-1 and thus can be used to detect the presence or level of PD-1 in a sample.
[0138] Therefore, in another aspect, the present invention provides a kit comprising an antibody or antigen-binding fragment thereof of the present invention. In a preferred embodiment, the antibody or antigen-binding fragment thereof of the present invention carries a detectable label. In another preferred embodiment, the kit further comprises a second antibody that specifically recognizes the antibody or antigen-binding fragment thereof of the present invention. Preferably, the second antibody further comprises a detectable label.
[0139] In the present invention, the detectable label can be any substance that can be detected by fluorescence, spectroscopy, photochemistry, biochemistry, immunology, electricity, optics or chemical means. It is particularly preferred that such labels can be used for immunological detection (e.g., enzyme-linked immunosorbent assay, radioimmunoassay, fluorescence immunoassay, chemiluminescence immunoassay, etc.). Such labels are well known in the art and include, but are not limited to, enzymes (e.g., horseradish peroxidase, alkaline phosphatase, β-galactosidase, urease, glucose oxidase, etc.), radionuclides (e.g., 3 H. 125 I. 35 S. 14 C or 32 P), fluorescent dyes (e.g., fluorescein isothiocyanate (FITC), fluorescein, tetramethylrhodamine isothiocyanate (TRITC), phycoerythrin (PE), Texas Red, rhodamine, quantum dots or cyanine dye derivatives (e.g., Cy7, Alexa 750)), luminescent substances (e.g., chemiluminescent substances such as acridinium ester compounds), magnetic beads (e.g., ), calorimetric labels such as colloidal gold or colored glass or plastic (e.g., polystyrene, polypropylene, latex, etc.) beads, and biotin for binding to avidin (e.g., streptavidin) modified with the above-mentioned labels. In certain embodiments, the detectable labels described above can be attached to the antibodies or antigen-binding fragments thereof of the present invention via linkers of varying lengths to reduce potential steric hindrance.
[0140] In another aspect, the present invention provides a method for detecting the presence or level of PD-1 in a sample, comprising the step of using an antibody or antigen-binding fragment thereof of the present invention. In a preferred embodiment, the antibody or antigen-binding fragment thereof of the present invention also carries a detectable label. In another preferred embodiment, the method further comprises detecting the antibody or antigen-binding fragment thereof of the present invention using a reagent with a detectable label. The method can be used for diagnostic purposes, or non-diagnostic purposes (for example, the sample is a cell sample, not a sample from a patient). In certain embodiments, the PD-1 is human PD-1.
[0141] In another aspect, a use of an antibody or antigen-binding fragment thereof of the present invention in preparing a kit for detecting the presence or level of PD-1 in a sample is provided. In certain embodiments, the PD-1 is human PD-1.
[0142] In certain embodiments, the sample is a cell sample (eg, a tumor cell) or a tissue sample (eg, a tumor tissue) from a subject (eg, a mammal, eg, a human).
[0143] Definition of terms
[0144] Unless otherwise indicated, scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Furthermore, the cell culture, biochemistry, nucleic acid chemistry, immunology, and other laboratory procedures used herein are conventional procedures widely used in the relevant fields. To facilitate a better understanding of the present invention, definitions and explanations of relevant terms are provided below.
[0145] As used herein, the term "antibody" refers to an immunoglobulin molecule typically composed of two pairs of polypeptide chains, each pair having one light chain (LC) and one heavy chain (HC). Antibody light chains can be classified as kappa (κ) and lambda (λ) light chains. Heavy chains can be classified as μ, δ, γ, α, or ε, and define the antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively. Within the light and heavy chains, the variable and constant regions are connected by a "J" region of approximately 12 or more amino acids, and the heavy chain also contains a "D" region of approximately 3 or more amino acids. Each heavy chain consists of a heavy chain variable region (VH) and a heavy chain constant region (CH). The heavy chain constant region consists of three domains (CH1, CH2, and CH3). Each light chain consists of a light chain variable region (VL) and a light chain constant region (CL). The light chain constant region consists of one domain, CL. The constant domain is not directly involved in the binding of antibodies to antigens, but exhibits a variety of effector functions, such as mediating the binding of immunoglobulins to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system. The VH and VL regions can also be subdivided into regions with high variability (called complementarity determining regions (CDRs)), interspersed with more conserved regions called framework regions (FRs). Each V H and V L It consists of three CDRs and four FRs arranged from amino terminus to carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions (VH and VL) of each heavy chain / light chain pair form the antigen-binding site. The allocation of amino acids within each region or domain can be based on the definitions of Kabat, Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991)), Chothia & Lesk (1987) J. Mol. Biol. 196:901-917; Chothia et al. (1989) Nature 342:878-883.
[0146] As used herein, the term "complementarity determining region" or "CDR" refers to the amino acid residues in the variable region of an antibody that are responsible for antigen binding. The precise boundaries of these amino acid residues can be defined according to various numbering systems known in the art, such as the Kabat numbering system (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991), the Chothia numbering system (Chothia & Lesk (1987) J. Mol. Biol. 196: 901-917; Chothia et al. (1989) Nature 342: 878-883), or the IMGT numbering system (Lefranc et al., Dev. Comparat. Immunol. 27: 55-77, 2003). For a given antibody, one skilled in the art will readily identify the CDRs defined by each numbering system. Furthermore, the correspondence between different numbering systems is well known to those skilled in the art (for example, see Lefranc et al., Dev. Comparat. Immunol. 27: 55-77, 2003).
[0147] In the present invention, the CDRs contained in the antibodies or antigen-binding fragments thereof of the present invention can be determined according to various numbering systems known in the art. In certain embodiments, the CDRs contained in the antibodies or antigen-binding fragments thereof of the present invention are determined by the numbering method described in Lu X, Nobrega RP, Lynaugh H, et al. Deamidation and isomerization liability analysis of 131 clinical-stage antibodies. MAbs. 2019 Jan; 11(1): 45-57. doi: 10.1080 / 19420862.2018.1548233. page 11, "Sequence analysis", the entire contents of which are incorporated herein by reference.
[0148] As used herein, the term "framework region" or "FR" residues refers to those amino acid residues in an antibody variable region other than the CDR residues as defined above.
[0149] The term "antibody" is not limited to any particular method of producing the antibody. For example, it includes recombinant antibodies, monoclonal antibodies, and polyclonal antibodies. The antibody can be of different isotypes, for example, IgG (e.g., IgG1, IgG2, IgG3, or IgG4 subtypes), IgA1, IgA2, IgD, IgE, or IgM antibodies.
[0150] As used herein, the term "antigen-binding fragment" of an antibody refers to a polypeptide comprising a fragment of a full-length antibody that retains the ability to specifically bind to the same antigen bound by the full-length antibody and / or competes with the full-length antibody for specific binding to the antigen, which is also referred to as an "antigen-binding portion." See generally, Fundamental Immunology, Ch. 7 (Paul, W., ed., 2nd ed., Raven Press, NY (1989), which is incorporated herein by reference in its entirety for all purposes. Antigen-binding fragments of antibodies can be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of intact antibodies. Non-limiting examples of antigen-binding fragments include Fab, Fab', F(ab')2, Fd, Fv, dAb and complementarity determining region (CDR) fragments, single-chain antibodies (e.g., scFv), chimeric antibodies, diabodies, linear antibodies, nanobodies (technology from Domantis), domain antibodies (technology from Ablynx), probodies, and polypeptides that comprise at least a portion of an antibody sufficient to confer specific antigen-binding ability on the polypeptide. Engineered antibody variants are reviewed in Holliger et al., 2005; Nat Biotechnol, 23: 1126-1136.
[0151] As used herein, the term "full-length antibody" means an antibody consisting of two "full-length heavy chains" and two "full-length light chains". Wherein, "full-length heavy chain" refers to a polypeptide chain that, in the direction from N-terminus to C-terminus, consists of a heavy chain variable region (VH), a heavy chain constant region CH1 domain, a hinge region (HR), a heavy chain constant region CH2 domain, and a heavy chain constant region CH3 domain; and, when the full-length antibody is an IgE isotype, optionally further comprises a heavy chain constant region CH4 domain. Preferably, a "full-length heavy chain" is a polypeptide chain consisting of VH, CH1, HR, CH2, and CH3 in the direction from N-terminus to C-terminus. A "full-length light chain" is a polypeptide chain consisting of a light chain variable region (VL) and a light chain constant region (CL) in the direction from N-terminus to C-terminus. The two pairs of full-length antibody chains are linked together by a disulfide bond between CL and CH1 and a disulfide bond between the HRs of the two full-length heavy chains. The full-length antibodies of the present invention can be derived from a single species, such as humans; they can also be chimeric antibodies or humanized antibodies. The full-length antibodies of the present invention comprise two antigen-binding sites formed by a VH and a VL pair, respectively, and the two antigen-binding sites specifically recognize / bind to the same antigen.
[0152] As used herein, the term "Fd fragment" means an antibody fragment consisting of the VH and CH1 domains; the term "dAb fragment" means an antibody fragment consisting of the VH domain (Ward et al., Nature 341:544-546 (1989)); the term "Fab fragment" means an antibody fragment consisting of the VL, VH, CL and CH1 domains; the term "F(ab')2 fragment" means an antibody fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; the term "Fab' fragment" means the fragment obtained after reducing the disulfide bonds linking the two heavy chain fragments in the F(ab')2 fragment, consisting of one complete light chain and the Fd fragment (consisting of the VH and CH1 domains) of the heavy chain.
[0153] As used herein, the term "Fv fragment" means an antibody fragment consisting of the VL and VH domains of a single arm of an antibody. An Fv fragment is generally considered to be the smallest antibody fragment that can form a complete antigen-binding site. It is generally believed that the six CDRs confer antigen-binding specificity to an antibody. However, even a single variable region (e.g., an Fd fragment containing only three CDRs specific for an antigen) can recognize and bind to an antigen, although its affinity may be lower than that of a complete binding site.
[0154] As used herein, the term "Fc fragment" refers to an antibody fragment formed by disulfide bonds between the second and third constant regions of the first heavy chain of an antibody and the second and third constant regions of the second heavy chain. The Fc fragment of an antibody has various functions but does not participate in antigen binding.
[0155] As used herein, the term "scFv" refers to a single polypeptide chain comprising a VL and VH domain, wherein the VL and VH are connected by a linker. Such scFv molecules may have a general structure: NH2-VL-linker-VH-COOH or NH2-VH-linker-VL-COOH. Suitable prior art linkers are composed of repeated GGGGS amino acid sequences or variants thereof. For example, a linker having the amino acid sequence (GGGGS) 4 may be used, but variants thereof may also be used (Holliger et al. (1993), Proc. Natl. Acad. Sci. USA 90: 6444-6448). In some cases, a disulfide bond may also be present between the VH and VL of an scFv. As used herein, the term "di-scFv" refers to an antibody fragment formed by connecting two scFvs.
[0156] As used herein, the term "diabodies" means antibodies whose VH and VL domains are expressed on a single polypeptide chain, but using a linker that is too short to allow pairing between the two domains on the same chain, thereby forcing the domains to pair with the complementary domains of another chain and create two antigen-binding sites (see, e.g., Holliger P. et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993), and Poljak RJ et al., Structure 2:1121-1123 (1994)).
[0157] Each of the above antibody fragments retains the ability to specifically bind to the same antigen as the full-length antibody, and / or competes with the full-length antibody for specific binding to the antigen.
[0158] Antigen-binding fragments of antibodies (e.g., those described above) can be obtained from a given antibody (e.g., an antibody provided herein) using conventional techniques known to those skilled in the art (e.g., recombinant DNA technology or enzymatic or chemical cleavage methods), and the antigen-binding fragments of antibodies can be screened for specificity in the same manner as for intact antibodies.
[0159] Herein, unless the context clearly indicates otherwise, when referring to the term "antibody", it includes not only intact antibodies, but also antigen-binding fragments of antibodies.
[0160] As used herein, the terms "monoclonal antibody," "single antibody," and "mAb" have the same meaning and are used interchangeably to refer to an antibody or an antibody fragment from a population of highly homologous antibody molecules, that is, a population of identical antibody molecules except for possible spontaneous natural mutations. A monoclonal antibody has high specificity for a single epitope on an antigen. Polyclonal antibodies, as opposed to monoclonal antibodies, typically contain at least two or more different antibodies, and these different antibodies typically recognize different epitopes on an antigen. In addition, the modifier "monoclonal" only indicates the characteristic of the antibody as being obtained from a population of highly homologous antibodies, and is not to be understood as requiring the antibody to be prepared by any particular method.
[0161] As used herein, the term "specific binding" refers to a non-random binding reaction between two molecules, such as an antibody and its antigen. The strength or affinity of a specific binding interaction can be measured by the equilibrium dissociation constant (K) of the interaction. D ) indicates. In the present invention, the term "K D " refers to the dissociation equilibrium constant of a specific antibody-antigen interaction, which is used to describe the binding affinity between the antibody and the antigen. The smaller the equilibrium dissociation constant, the tighter the antibody-antigen binding and the higher the affinity between the antibody and the antigen. In certain embodiments, an antibody that specifically binds to an antigen (or has specificity for an antigen) refers to an antibody that binds to an antigen with a specificity of less than about 10 -9 M, for example, less than about 10 -9 M, 10 -10 M, 10 -11 M or 10 -12 Affinity of M or less (K D The specific binding properties between the two molecules can be determined using methods well known in the art, such as surface plasmon resonance (SPR) in a BIACORE instrument.
[0162] As used herein, the term "vector" refers to a nucleic acid delivery vehicle into which a polynucleotide can be inserted. When a vector is capable of expressing a protein encoded by the inserted polynucleotide, it is referred to as an expression vector. A vector can be introduced into a host cell via transformation, transduction, or transfection, allowing the genetic material it carries to be expressed in the host cell. Vectors are well known to those skilled in the art and include, but are not limited to, plasmids; phagemids; cosmids; artificial chromosomes, such as yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), or P1-derived artificial chromosomes (PACs); bacteriophages, such as lambda phage or M13 phage, and animal viruses. Animal viruses that can be used as vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (such as herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, and papillomas (such as SV40). A vector can contain a variety of elements that control expression, including, but not limited to, promoter sequences, transcription initiation sequences, enhancer sequences, selection elements, and reporter genes. Additionally, a vector may contain an origin of replication.
[0163] As used herein, the term "host cell" refers to a cell that can be used to introduce a vector, including but not limited to prokaryotic cells such as Escherichia coli or Bacillus subtilis, fungal cells such as yeast cells or Aspergillus, insect cells such as S2 Drosophila cells or Sf9, or animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK 293 cells or human cells.
[0164] As used herein, the term "identity" refers to the match between two polypeptides or between two nucleic acids. When a position in both sequences being compared is occupied by the same base or amino acid monomer subunit (e.g., a position in each of the two DNA molecules is occupied by adenine, or a position in each of the two polypeptides is occupied by lysine), then the molecules are identical at that position. The "percent identity" between two sequences is a function of the number of matching positions shared by the two sequences divided by the number of positions compared x 100. For example, if 6 out of 10 positions in two sequences match, then the two sequences have 60% identity. For example, the DNA sequences CTGACT and CAGGTT share 50% identity (3 out of 6 positions match). Typically, two sequences are compared when they are aligned for maximum identity. Such an alignment can be achieved, for example, by using the method of Needleman et al. (1970) J. Mol. Biol. 48:443-453, which can be conveniently performed using a computer program such as the Align program (DNAstar, Inc.). The percent identity between two amino acid sequences can also be determined using the algorithm of E. Meyers and W. Miller (Comput. Appl Biosci., 4:11-17 (1988)), which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4. In addition, the percent identity between two amino acid sequences can be determined using the Needleman and Wunsch (J Mol Biol. 48:444-453 (1970)) algorithm, which has been incorporated into the GAP program in the GCG software package (available at www.gcg.com), using a Blossum 62 matrix or a PAM250 matrix and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.
[0165] As used herein, the term "conservative substitution" means an amino acid substitution that does not adversely affect or change the expected properties of the protein / polypeptide comprising the amino acid sequence. For example, conservative substitutions can be introduced by standard techniques known in the art such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions include substitutions of amino acid residues with amino acid residues having similar side chains, such as substitutions of residues physically or functionally similar to corresponding amino acid residues (e.g., having similar size, shape, charge, chemical properties, including the ability to form covalent bonds or hydrogen bonds, etc.). Families of amino acid residues with similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, and histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, it is preferred to replace the corresponding amino acid residue with another amino acid residue from the same side chain family. Methods for identifying conservative amino acid substitutions are well known in the art (see, e.g., Brummell et al., Biochem. 32: 1180-1187 (1993); Kobayashi et al. Protein Eng. 12(10): 879-884 (1999); and Burks et al. Proc. Natl Acad. Set USA 94: 412-417 (1997), which are incorporated herein by reference).
[0166] The twenty conventional amino acids referred to herein are written in accordance with conventional usage. See, for example, Immunology—A Synthesis (2nd Edition, E.S. Golub and D.R. Gren, Eds., Sinauer Associates, Sunderland, Mass. (1991)), which is incorporated herein by reference. In the present invention, the terms "polypeptide" and "protein" have the same meaning and are used interchangeably. Also, in the present invention, amino acids are generally represented by single-letter and three-letter abbreviations known in the art. For example, alanine can be represented by A or Ala.
[0167] As used herein, the term "pharmaceutically acceptable carrier and / or excipient" refers to a carrier and / or excipient that is pharmacologically and / or physiologically compatible with the subject and the active ingredient, which is well known in the art (see, for example, Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995) and includes, but is not limited to, pH adjusters, surfactants, adjuvants, ionic strength enhancers, diluents, agents that maintain osmotic pressure, agents that delay absorption, and preservatives. For example, pH adjusters include, but are not limited to, phosphate buffers. Surfactants include, but are not limited to, cationic, anionic, or nonionic surfactants, such as Tween-80. Ionic strength enhancers include, but are not limited to, sodium chloride. Preservatives include, but are not limited to, various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, and the like. Agents that maintain osmotic pressure include, but are not limited to, sugars, NaCl, and the like. Agents that delay absorption include, but are not limited to, monostearate and gelatin. Diluents include, but are not limited to, water, aqueous buffers (e.g., buffered saline), alcohols, and polyols (e.g., glycerol). Preservatives include, but are not limited to, various antibacterial and antifungal agents, such as thimerosal, 2-phenoxyethanol, parabens, chlorobutanol, phenol, sorbic acid, and the like. Stabilizers have the meaning generally understood by those skilled in the art, and are capable of stabilizing the desired activity of the active ingredient in the drug, including, but not limited to, sodium glutamate, gelatin, SPGA, carbohydrates (e.g., sorbitol, mannitol, starch, sucrose, lactose, dextran, or glucose), amino acids (e.g., glutamic acid, glycine), proteins (e.g., dried whey, albumin, or casein), or degradation products thereof (e.g., lactalbumin hydrolyzate), and the like. In certain exemplary embodiments, the pharmaceutically acceptable carrier or excipient comprises a sterile injectable liquid (e.g., an aqueous or non-aqueous suspension or solution). In certain exemplary embodiments, such sterile injectable liquids are selected from water for injection (WFI), bacteriostatic water for injection (BWFI), sodium chloride solution (e.g., 0.9% (w / v) NaCl), glucose solution (e.g., 5% glucose), a solution containing a surfactant (e.g., 0.01% polysorbate 20), a pH buffered solution (e.g., phosphate buffered solution), Ringer's solution, and any combination thereof.
[0168] As used herein, the term "prevention" refers to a method implemented in order to prevent or delay the occurrence of a disease or illness or symptom (e.g., a tumor or infection) in a subject. As used herein, the term "treatment" refers to a method implemented in order to obtain a beneficial or desired clinical outcome. For purposes of the present invention, beneficial or desired clinical outcomes include, but are not limited to, alleviating symptoms, reducing the scope of the disease, stabilizing (i.e., no longer worsening) the state of the disease, delaying or slowing the development of the disease, improving or alleviating the state of the disease, and alleviating symptoms (whether partially or entirely), whether detectable or undetectable. In addition, "treatment" can also refer to, compared to the expected survival (if not receiving treatment), extending the survival period.
[0169] As used herein, the term "subject" refers to a mammal, such as a primate mammal, such as a human. In certain embodiments, the subject (eg, human) suffers from a tumor or infection, or is at risk of suffering from the above diseases.
[0170] As used herein, the term "effective amount" refers to an amount sufficient to obtain or at least partially obtain the desired effect. For example, an effective amount for preventing a disease (e.g., a tumor or infection) refers to an amount sufficient to prevent, stop, or delay the occurrence of a disease (e.g., a tumor or infection); an effective amount for treating a disease refers to an amount sufficient to cure or at least partially stop the disease and its complications in a patient already suffering from the disease. Determining such an effective amount is well within the capabilities of those skilled in the art. For example, an amount effective for therapeutic use will depend on the severity of the disease to be treated, the overall state of the patient's own immune system, the patient's general condition such as age, weight and sex, the mode of administration of the drug, and other treatments administered simultaneously, etc.
[0171] Advantageous Effects of the Invention
[0172] The antibodies of the present invention can not only specifically recognize / bind to PD-1 and block the binding of PD-1 to PD-L1, but also enhance immune cell activity in vitro / in vivo and stimulate immune responses. Therefore, the antibodies of the present invention have the potential to be used to prevent and / or treat tumors or infections. In addition, the present invention also provides a fusion protein comprising the antibodies of the present invention and a TGF-β / TGF-βR pathway inhibitor, which simultaneously specifically binds to PD-1 and TGF-β and blocks the PD-L1 / PD-1 and TGF-β / TGF-βR pathways, relieving T cell immunosuppression, better exerting anti-tumor activity, improving the objective response rate of tumor patients, and prolonging the survival of tumor patients.
[0173] The embodiments of the present invention will be described in detail below with reference to the accompanying drawings and examples, but it will be understood by those skilled in the art that the following drawings and examples are intended only to illustrate the present invention and are not intended to limit the scope of the invention. Various objects and advantages of the present invention will become apparent to those skilled in the art based on the following detailed description of the drawings and preferred embodiments. BRIEF DESCRIPTION OF THE DRAWINGS
[0174] Figure 1A: Binding curve of anti-PD-1 antibody / scFv to human PD-1 overexpressed on CHO cells.
[0175] Figure 1B: Binding curve of anti-PD-1 antibody / scFv to cynomolgus monkey PD-1 overexpressed on CHO cells.
[0176] Figure 2: Graph showing anti-PD-1 antibody / scFv blocking the binding of human PD-L1 to human PD-1 overexpressed on CHO cells.
[0177] FIG3 : Graph showing the binding of anti-PD-1 antibodies / scFv to PD-1 on activated human primary T cells.
[0178] Figure 4: Graph showing blocking of PD-L1 / PD-1 luciferase reporter gene by anti-PD-1 antibody / scFv.
[0179] Figure 5: Bar graph showing IL-2 secretion stimulated by anti-PD-1 antibody / scFv in mixed lymphocyte assay.
[0180] Figure 6: Pharmacodynamics of anti-PD-1 antibodies in the h-PD-1 KI mouse h-PD-L1 KI MC38 tumor model.
[0181] Figure 7: Pharmacological efficacy of anti-PD-1 antibody in the B-NDG B2M KO plus mouse A375 tumor model.
[0182] Figure 8: Schematic diagram of the molecular structure of the anti-PD-1 / TGF-β dual antibody 54872-TGF-βRⅡ.
[0183] Figure 9A: Binding curve of the anti-PD-1 / TGF-β dual antibody 54872-TGF-βRⅡ and human PD-1 overexpressed on CHO cells.
[0184] Figure 9B: Binding curve of the anti-PD-1 / TGF-β dual antibody 54872-TGF-βRⅡ and cynomolgus monkey PD-1 overexpressed in CHO cells.
[0185] Figure 10: Curve graph of the anti-PD-1 / TGF-β dual antibody 54872-TGF-βRⅡ blocking the binding of human PD-L1 to human PD-1 overexpressed on CHO cells.
[0186] Figure 11: Curve graph of the anti-PD-1 / TGF-β dual antibody 54872-TGF-βRⅡ blocking the PD-L1 / PD-1 luciferase reporter gene.
[0187] Figures 12A to 12C are graphs showing the binding of the anti-PD-1 / TGF-β dual antibody 54872-TGF-βRⅡ to human TGF-β1, TGF-β2, and TGF-β3.
[0188] Figure 13: Curve diagram of the blocking effect of anti-PD-1 / TGF-β dual antibody 54872-TGF-βRⅡ on TGF-β1 / SMAD.
[0189] Figure 14A: Co-binding curve of 54872-TGF-βRⅡ molecule with human PD-1 protein and anti-TGF-bR2 antibody ELISA level (anti-TGF-βR2 antibody coated with human PD-1 protein to detect Biotin).
[0190] Figure 14B: Co-binding curve of 54872-TGF-βRⅡ molecule with TGF-β1 and human PD-1 protein ELISA level (PD-1 protein coated with TGF-β1 to detect Biotin curve (anti-TGF-βR2 antibody coated with human PD-1 protein to detect Biotin).
[0191] Figure 15: A graph showing that the binding of TGF-β1 does not affect the binding of 54872-TGF-βRⅡ molecules to CHO cells overexpressing human PD-1.
[0192] Figure 16: Whether TGF-β1 binds or not does not affect the curve graph showing that 54872-TGF-βRⅡ molecules block the binding of human PD-L1 to human PD-1 overexpressed on CHO cells.
[0193] Figures 17A-17B: Bar graphs showing the stimulation of IL-2 and IFN-γ secretion by the 54872-TGF-βRII molecule in a mixed lymphocyte assay.
[0194] Figure 18: Pharmacological efficacy of 54872-TGF-βRⅡ molecule in B-NDG B2M KO plus mouse A375 tumor model.
[0195] Figure 19: Curve of the change in blood concentration of 54872-TGF-βRⅡ molecule in mice over time.
[0196] Sequence information
[0197] Information on sequences related to the present invention is provided in Table 1 below.
[0198] Table 1: Description of sequences Example
[0199] The present invention will now be described with reference to the following examples, which are intended to illustrate the present invention (but not to limit the present invention). Unless otherwise specified, the molecular biology experimental methods and immunoassays used in the present invention are basically based on the methods described in J. Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory Press, 1989, and F.M. Ausubel et al., Molecular Biology: A Laboratory Manual, 3rd edition, John Wiley & Sons, Inc., 1995; the use of restriction endonucleases is in accordance with the conditions recommended by the product manufacturers. It will be appreciated by those skilled in the art that the examples describe the present invention by way of example and are not intended to limit the scope of protection claimed in the present invention.
[0200] The control antibody Pembrolizumab involved in the present invention is an anti-PD-1 monoclonal antibody with the trade name Keytruda, which is an original drug produced by Merck.
[0201] Example 1: Antibody screening, sequence design, expression and purification
[0202] 1. Animal immunization and single cell sorting
[0203] 6- to 8-week-old BALB / c mice were subcutaneously immunized with a mouse IgG1 Fc fusion protein of the PD-1 extracellular domain (Genbank sequence number: AY238517) and Ribi adjuvant (Sigma) at a dose of 10 μg / mouse. Boost immunizations were then performed with an intraperitoneal injection of 10 μg / mouse of a PD-1 extracellular domain-his fusion protein. Mice were euthanized, and spleens and lymph nodes were harvested, placed on a cell sieve, gently triturated, and rinsed with PBS to obtain a single-cell suspension. Cells were incubated with biotin-labeled PD-1 protein and a fluorescent secondary antibody conjugated to biotin, washed, resuspended in FACS buffer, and sorted on a flow cytometer. Single cells were sorted into 96-well PCR plates (BioRad). Each well contained 20 μL of lysis buffer (5 μL of 5X single-stranded cDNA buffer (Invitrogen), 0.625 μL of NP-40 (New England Biolabs), 0.25 μL of RNaseOUT (Invitrogen), 1.25 μL of dithiothreitol (Invitrogen), and 12.6 μL of double-distilled water). After sorting, the plates were immediately transferred to −80°C for storage.
[0204] 2. Single B cell antibody variable region sequence cloning and amplification
[0205] Based on a previous report (Tiller et al. 2009 J Immunol Methods 350:183-93), cDNA sequences encoding the antibody heavy and light chain variable regions were amplified from B cell lysates using a mixture of IgG and IgM-specific primers via reverse transcription-PCR and nested PCR. 10 μL of the PCR-amplified heavy and light chain variable region sequences were co-transfected with 200 ng of enzyme-digested yeast expression plasmid into yeast cells. Subsequent enrichment, amplification, antibody expression, screening, and sequencing were performed on the transfected single yeast cells.
[0206] 3. Humanized modification of anti-PD-1 antibodies
[0207] For example, to reduce the potential immunogenicity of mouse antibodies, humanized antibodies are modified. Generally speaking, humanized antibodies contain the CDR region of non-human antibodies and the framework and constant regions of human antibodies. In some cases, some amino acids in the human antibody framework region are also reversed to better maintain the activity of the antibody. Humanization was performed according to previous reports (Imagro et al. Front. Biosci. 13: 1619-1633 (2008); Riechmann et al. Nature 332: 323-329 (1988); Queen et al. Proc. Nat'l Acad. Sci. USA 86: 10029-10033 (1989); US Pat. Nos. 5,821,337, 7,527,791, 6,982,321, 7,087,409; Kashmiri et al. Methods 36: 25-34 (2005); Padlan, Mol. Immunol. 28: 489-498 (1991); Dall'Acqua et al. Methods 36: 43-60 (2005)). Methods for selecting human antibody framework regions include, but are not limited to, the "optimal selection method" (Sims et al. J. Immunol. 151: 2296 (1993)). The antibody framework region is derived from the heavy and light chain variable region library sequence alignment method (Carter et al. Proc. Natl. Acad. Sci. USA, 89: 4285 (1992), etc. The humanized antibody modification of the present invention is based on computational biological selection of the humanized antibody sequence library and the most suitable human antibody framework region of the mouse antibody, and the mouse antibody CDR region is grafted onto the human framework region. For each humanized parent antibody, 3 to 4 optimal human antibody heavy chain variable regions and 3 to 4 optimal human antibody light chain variable regions are selected and constructed according to the above method. The antibodies are transfected into yeast for expression and screening for binding to human monkey PD-1 protein.
[0208] 4. Antibody Engineering Optimization
[0209] Further engineering optimization of the humanized monoclonal antibody / scFv was performed as follows: random point mutations were performed on the antibody heavy chain variable region CDR1, 2, and 3, and the cells were paired with the original light chain to be transfected into yeast. A yeast population with improved affinity was screened and a heavy chain affinity plasmid library was extracted. Random point mutations were performed on the antibody light chain variable region CDR1, 2, and 3, and the cells were paired with the original heavy chain to be transfected into yeast. A yeast population with improved affinity was screened and a light chain affinity plasmid library was extracted. The heavy and light chain affinity plasmid libraries were randomly mixed and transfected into yeast for library screening. Finally, yeast clones with improved affinity were obtained and sequenced to obtain the affinity-enhanced antibody sequence.
[0210] Screening and engineering using the above methods ultimately yielded the anti-PD-1 antibody ADI-54872. Based on the variable region sequence of ADI-54872, its derivative (anti-PD-1 scFv molecule) was further generated, designated ADI-54872-1. ADI-54872-1 was further engineered to yield its derivative, ADI-63628. The full-length sequences of ADI-54872-1 and ADI-63628 are shown in SEQ ID NOs: 23 and 24, respectively, and comprise the IgG1 CH2 / CH3 constant region sequence (SEQ ID NO: 22) and scFv sequence (VH-linker-VL). The CDR and variable region sequences of the anti-PD-1 antibody and its scFv derivative are shown in the table below.
[0211] Table 2: Antibody CDR and variable region sequences
[0212] The amino acid sequence of the ADI-54872 heavy chain variable region was linked to the amino acid sequence of the heavy chain constant region (SEQ ID NO: 15), and the amino acid sequence of the ADI-54872 light chain variable region was linked to the amino acid sequence of the light chain constant region (SEQ ID NO: 16). These sequences were cloned into the pcDNA3.1 expression vector and transiently expressed and purified using the HEK293 expression system. The amino acid sequences of ADI-54872-1 (SEQ ID NO: 23) and ADI-63628 (SEQ ID NO: 24) were cloned into the pcDNA3.1 expression vector and transiently expressed and purified using the HEK293 expression system. Specifically, the pcDNA3.1 vector carrying the antibody heavy and / or light chain was chemically transfected into HEK293 cells and cultured at 37°C, 8% CO2 for 7 days. The cell suspension was collected and centrifuged at 13,000 rpm for 20 minutes. The supernatant was collected and purified by Protein A. The antibody purity was tested by SEC and the endotoxin content was also controlled.
[0213] Example 2: Antibody affinity detection
[0214] The binding dissociation constants (KD) of the antibodies obtained in Example 1 for binding to human and cynomolgus monkey PD-1 were determined using biofilm optical interferometry (ForteBio). Fortebio affinity determination was performed according to existing methods (Este, P et al., High throughput solution-based measurement of antibody-antigen affinity and epitope binning. Mabs, 2013. 5(2): p. 270-8). The amino acid sequences of the extracellular domains of human and cynomolgus monkey PD-1 are shown in SEQ ID NOs: 20 and 21, respectively.
[0215] To measure the monovalent affinity of intact antibodies (full-length IgG) or anti-PD-1 Fc-scFv proteins for human and cynomolgus monkey PD-1-his proteins, the sensor was equilibrated offline in assay buffer for 20 minutes, followed by 120 seconds of online measurement to establish a baseline. The intact PD-1 antibody or Fc-scFv was then loaded onto the AHQ sensor to a thickness of 1 nm for affinity measurement. The antibody-loaded sensor was incubated with 100 nM PD-1-his antigen until plateau, and then the sensor was transferred to assay buffer for at least 2 minutes for dissociation rate measurement. Kinetic analysis was performed using a 1:1 binding model.
[0216] The results are shown in the table below. ADI-54872, ADI-54872-1, and ADI-63628 bind to human and cynomolgus monkey PD-1 proteins with superior monovalent affinity to the control antibody pembrolizumab.
[0217] Table 3: Antibody KD values
[0218] Example 3: Binding activity of anti-PD-1 antibodies / scFv to CHO cells overexpressing human / cynomolgus monkey PD-1
[0219] CHO-S cells overexpressing human PD-1 (CHO-huPD-1 cells) and CHO-S cells overexpressing cynomolgus monkey PD-1 (CHO-cynoPD-1 cells) were generated by pressure screening by transfection of the pCHO1.0 vector (purchased from Invitrogen) cloned with the human PD-1 (Uniprot: Q15116) and cynomolgus monkey PD-1 (Uniprot: B0LAJ3) cDNAs of MCS. The expanded overexpressing cells were adjusted to an appropriate cell density and added to a 96-well flow cytometry plate. After centrifugation, the test samples were added with gradient dilutions and incubated at 4°C for 30 minutes. The cells were washed twice with PBS, and the fluorescent secondary antibody diluted to the appropriate concentration was added, incubated at 4°C for 30 minutes, and washed twice with PBS. The cells were resuspended in PBS, detected on a CytoFlex flow cytometer, and the corresponding MFI was calculated. Graphpad software was used for graphical analysis to obtain the EC50 value. The results are shown in Table 4 and Figures 1A and 1B: ADI-54872, ADI-54872-1, and ADI-63628 have good binding activity to CHO cells overexpressing human PD-1 and cynomolgus monkey PD-1.
[0220] Table 4: Summary of binding and blocking activities of anti-PD-1 antibodies / scFv in overexpressing cells
[0221] Example 4: Anti-PD-1 antibody / scFv blocks PD-L1 binding activity to CHO cells overexpressing human PD-1
[0222] The cell density of the expanded cultured CHO-huPD-1 cells was adjusted to 2×10 6 / mL, 100 μL / well was added to a 96-well flow cytometer, centrifuged, and then used. The purified monoclonal antibody was diluted with PBS, starting at 400 nM and diluted 3-fold for a total of 12 points. 60 μL / well of the diluted sample was added to the 96-well flow cytometer containing cells and incubated at 4°C for 30 minutes. Then, 60 μL / well of bio-human PD-L1-Fc protein was added to a final concentration of 0.5 μg / mL. The cells were incubated at 4°C for 30 minutes and washed twice with PBS. 100 μL / well of SA-PE diluted 100-fold in PBS was added. The cells were incubated at 4°C for 30 minutes and washed twice with PBS. The cells were resuspended in 100 μL / well of PBS and analyzed on a CytoFlex flow cytometer, and the corresponding MFI was calculated. The results are shown in Table 4 and Figure 2: ADI-54872, ADI-54872-1, and ADI-63628 exhibited excellent blocking activity.
[0223] Example 5: Anti-PD-1 antibody / scFv binds to PD-1 on the surface of primary T cells
[0224] The binding activity of the invented anti-PD-1 antibody / scFv to PD-1 on the surface of activated T cells was detected based on flow cytometry.
[0225] Specifically, human PBMCs were sorted according to the protocol provided by STEMCELL (STEMCELL, catalog number: #17951C) to obtain human total T cells. The T cell concentration was adjusted to 1.0×10 6 To the cells, 1 μL of IL-2 stock solution (1 million IU) was added, along with CD3 / CD28 Dynabeads (Gibco, Cat. No. 11132D) in a 1:1 ratio (bead-to-cell ratio). The cells were cultured at 37°C in a 5% CO2 incubator for 48 hours. The activated T cells were adjusted to an appropriate cell density and plated onto a 96-well flow cytometry plate. After centrifugation, serially diluted samples were added and incubated at 4°C for 30 minutes. The cells were washed twice with PBS, and fluorescent secondary antibodies diluted to the appropriate concentration were added. The cells were incubated at 4°C for 30 minutes, and then washed twice with PBS. The cells were resuspended in PBS, analyzed on a CytoFlex flow cytometer, and the corresponding MFI was calculated. As shown in Figure 3, the anti-PD-1 antibodies / scFvs ADI-54872, ADI-54872-1, and ADI-63628 of the present invention can bind to the PD-1 molecule on the surface of activated T cells, with ADI-54872 outperforming the control antibody pembrolizumab.
[0226] Example 6: Anti-PD-1 antibody / scFv blocking PD-L1 / PD-1 luciferase reporter gene assay
[0227] To further detect the blocking activity of PD-1 antibodies / scFv at the cellular level, a luciferase reporter gene system was constructed in this example. Briefly, lentiviral transfection was used to construct a CHO-K1 cell line overexpressing human PD-L1 and OKT-3 scFv (CHO-K1-PD-L1), and a Jurkat cell line overexpressing human PD-1 and NF-AT luciferase reporter genes (purchased from Promega) (Jurkat-PD-1-luc) was constructed. This reporter gene system was subsequently used to carry out related experiments.
[0228] Specifically, CHO-K1-PD-L1 functional cells were obtained by digestion, the cell density was adjusted, 100 μL / well was added to a 96-well white bottom plate, and cultured overnight. The next day, a Jurkat-PD-1-luc effector cell suspension was prepared, and the sample to be tested was diluted with a reaction medium (RPMI1640 + 10% FBS). The white bottom plate was removed, the culture supernatant was aspirated, 40 μL / well of the diluted sample was added to the white bottom plate, and 40 μL / well of the Jurkat-TIGIT-luc effector cell suspension was added. The cells were placed in a 37°C, 5% CO2 incubator and cultured for 6 hours. During this period, the Bio-Glo™ reagent (purchased from promega, catalog number: G7940) was returned to room temperature. After the culture was completed, the cells were removed, equilibrated at room temperature for 5 minutes, 80 μL / well of the Bio-Glo™ reagent was added, and the fluorescence signal value was read using a multifunctional microplate reader. The results are shown in FIG4 . The anti-PD-1 antibodies / scFv ADI-54872, ADI-54872-1, and ADI-63628 of the present invention can block the PD-1 downstream signaling pathway mediated by PD-L1 and upregulate the expression of the reporter gene luciferase.
[0229] Example 7: Mixed lymphocyte reaction assay
[0230] In this example, the activity of PD-1 antibody / scFv in activating T cells was detected by mixed lymphocyte reaction (MLR) assay. The specific test method is as follows.
[0231] PBMC cells (purchased from SAILY BIO, SLB-HPB) were resuspended in 10 ml X-VIVO-15 medium (purchased from LONZA) and cultured in a cell culture incubator at 37°C for 2 h. Non-adherent cells were removed by aspiration. 10 ml DC culture medium was added: X-VIVO-15 medium supplemented with 10 ng / ml GM-CSF (purchased from R&D) and 20 ng / ml IL-4. Culture was continued for 3 days. 5 ml DC culture medium was added and culture was continued until day 6. DC maturation medium was added: X-VIVO-15 medium supplemented with 1000 U / ml TNF-α (purchased from R&D), 10 ng / ml IL-6 (purchased from R&D), 5 ng / ml IL-1β (purchased from R&D), and 1 μM PGE2 (purchased from Tocris). Culture was continued for 2 days. Mature DC cells were collected and the cell density was adjusted to 2 × 10 with X-VIVO-15 medium. 5 / ml.
[0232] PBMC cells from another donor (purchased from SAILY BIO, SLB-HPB) were revived, centrifuged, and resuspended in 10 ml of X-VIVO-15 medium. Total T cells were enriched using a total T cell isolation kit (purchased from Stemcell) and resuspended in X-VIVO-15 to adjust the cell density to 2×10 6 / ml. T cells were mixed with the mature DC cells collected above at a ratio of 1:1, and 100 μl / well was added to a 96-well U-bottom plate.
[0233] PD-1 antibody / scFv was diluted with X-VIVO-15 medium, starting at 200 nM and diluted 5-fold for a total of 5 points. 100 μl / well was added to the above mixed cell wells and cultured for 3 days. The supernatant was collected and the IL2 expression level was detected by ELISA (purchased from eBioscience).
[0234] The results are shown in FIG5 . The anti-PD-1 antibodies / scFv ADI-54872, ADI-54872-1, and ADI-63628 of the present invention can activate T cells to secrete IL-2 in the MLR test, and the activation activity of ADI-54872 is superior to that of the control antibody pembrolizumab.
[0235] Example 8: Pharmacodynamic study of anti-PD-1 antibodies in human PD-1 transgenic mice
[0236] In this experiment, human PD-L1 KI MC38 tumor cells (MC38-huPD-L1 cells) were subcutaneously inoculated into human PD-1 transgenic C57 mice (huPD-1 KI mice) to determine the anti-tumor effect of the PD-1 antibody of the present invention.
[0237] Specifically, a MC38-huPD-L1 cell tumor-bearing mouse model was first established by subcutaneous inoculation. When the average tumor volume reached approximately 173 mm3, the mice were grouped and treated with PBS, 5 mg / kg ADI-54872, and 5 mg / kg pembrolizumab via intraperitoneal injection. Tumor volume and body weight changes in each group of mice were monitored every 2-4 days for 3 consecutive weeks. The dosage and administration method are shown in Table 5. The results, as shown in Figure 6, demonstrate that the anti-PD-1 antibody ADI-54872 of the present invention exhibits significant anti-tumor activity.
[0238] Table 5: Dosing regimen of anti-PD-1 antibodies
[0239] Example 9: In vivo pharmacodynamic study of anti-PD-1 antibodies in B-NDG mice inoculated with A375 and human PBMCs
[0240] In this experiment, the anti-tumor activity of the anti-PD-1 antibody of the present invention was determined in a tumor model in which B-NDG mice were co-inoculated with A375 and human PBMC.
[0241] Specifically, an A375 tumor-bearing mouse model was first established by subcutaneously inoculating a mixed A375+PBMC inoculation. When the average tumor volume reached approximately 147 mm³, the mice were grouped and treated with PBS, 2.1 mg / kg ADI-54872, and 2.1 mg / kg pembrolizumab via intraperitoneal injection. Changes in tumor volume and body weight were monitored every two days for two weeks. The dosage and administration method are shown in Table 6. The results, as shown in Figure 7, demonstrate that the anti-PD-1 antibody ADI-54872 of the present invention exhibits significant anti-tumor activity.
[0242] Table 6: Dosing regimen of anti-PD-1 antibodies
[0243] Example 10: Cloning and expression of anti-PD-1 / TGF-βtrap fusion protein
[0244] In this example, the TGF-βR2 extracellular domain (SEQ ID NO: 19) was used as the immunomodulatory molecule portion of the fusion protein, and the PD-1 antibody was used as the targeting portion of the fusion protein to form a PD-1 antibody / TGF-βRII extracellular region fusion protein, named 54872-TGF-βRⅡ.
[0245] Using molecular cloning technology, the C-terminal amino acid of the heavy chain of ADI-54872 was linked to the extracellular domain of TGF-βRII via (G4A)4G. Conventional expression was performed using the Expi-CHO expression system. The expression and purification methods were the same as in Example 1 to obtain the fusion protein 54872-TGF-βRⅡ with the structure shown in Figure 8. The full-length heavy chain sequence and light chain sequence are shown in SEQ ID NO: 17 and SEQ ID NO: 18, respectively.
[0246] Example 11: Binding activity of 54872-TGF-βRⅡ molecule to CHO cells overexpressing human / cynomolgus monkey PD-1
[0247] The method for detecting the binding activity of the purified PD-1 antibody ADI-54872, 54872-TGF-βRⅡ molecule, and TGF-βR2-Fc fusion protein to cell surface PD-1 is the same as in Example 3. In the assay experiment using the above method, the experimental results are shown in Figures 9A-9B, showing that the 54872-TGF-βRⅡ molecule of the present invention has binding activity to CHO cells overexpressing human PD-1 and cynomolgus monkey PD-1.
[0248] Example 12: 54872-TGF-βRⅡ molecule blocks the binding activity of PD-L1 to CHO cells overexpressing human PD-1
[0249] The method for detecting the binding activity of purified PD-1 antibody ADI-54872, 54872-TGF-βRⅡ molecule, and TGF-βR2-Fc fusion protein in blocking PD-L1 and human PD-1 overexpressing CHO cells was the same as in Example 4. In the assay experiment using the above method, the experimental results are shown in Figure 10, indicating that the 54872-TGF-βRⅡ molecule of the present invention can block the binding of PD-L1 to human PD-1 overexpressing CHO cells.
[0250] Example 13: 54872-TGF-βRⅡ molecule blocking PD-L1 / PD-1 luciferase reporter gene assay
[0251] The method for detecting the ability of purified PD-1 antibody ADI-54872, 54872-TGF-βRⅡ molecule, TGF-βR2-Fc fusion protein, and negative control to block the PD-L1-mediated PD-1 downstream signaling pathway at the cellular level was the same as in Example 6. In the assay experiment using the above method, the experimental results are shown in Figure 11. The 54872-TGF-βRⅡ molecule of the present invention can block the PD-L1-mediated PD-1 downstream signaling pathway and upregulate the expression of the reporter gene luciferase.
[0252] Example 14: ELISA binding experiment of 54872-TGF-βRⅡ molecule and human TGF-β family protein
[0253] Human TGF-β1 (Acrobiosystems, TG1-H421), TGF-β2 (PeproTech, 100-35B), and TGF-β3 (PeproTech, 100-36E) proteins were diluted in ELISA coating buffer and added to the ELISA plate. Coating was incubated overnight at 4°C. The coating buffer was discarded, and the plate was washed three times with 250 μL / well of PBST. The plate was then blocked with 5% BSA for 1 hour at room temperature. Purified PD-1 antibody ADI-54872, 54872-TGF-βRⅡ molecules, TGF-βR2-Fc fusion protein, and a negative control were serially diluted in 1% BSA and added to the blocked ELISA plate. The plate was incubated for 2 hours at room temperature. After washing three times with PBST, mouse anti-human Fc-HRP (Southern Biotech, 9040-05) was added to the wells and incubated at room temperature for 1 hour. After washing three times with PBST, ELISA colorimetric solution was added and the wells were allowed to stand at room temperature for 3 minutes. After that, ELISA stop solution was added and the absorbance at 450 nm was read.
[0254] In the assay experiment using the above method, the experimental results are shown in Figures 12A-12C. The 54872-TGF-βRⅡ molecule of the present invention has good binding activity with human TGF-β1 and TGF-β3 proteins at the ELISA level, but weak binding activity with human TGF-β2 protein.
[0255] Example 15: Experiment on blocking TGF-β / SMAD signaling pathway by 54872-TGF-βRⅡ molecule
[0256] An appropriate number of 293-TGF-β / SMAD effector cells were seeded into 96-well white-bottom cell culture plates and incubated overnight at 37°C in a 5% CO2 incubator. Purified PD-1 antibody ADI-54872, 54872-TGF-βRⅡ molecules, TGF-βR2-Fc fusion protein, and a negative control were serially diluted and mixed with TGF-β1 (Acrobiosystems, TG1-H421) and incubated at room temperature for 30 minutes. The mixture was added to the white-bottom plate containing cells and incubated overnight. Bio-Glo™ reagent (Promega) was added to each well, and the fluorescence signal was read using a multi-function microplate reader.
[0257] In the assay experiment using the above method, the experimental results are shown in FIG13 , indicating that the 54872-TGF-βRⅡ molecule of the present invention can block the TGF-β / SMAD signaling pathway in vitro.
[0258] Example 16: ELISA level co-binding experiment of 54872-TGF-βRⅡ molecule and human TGF-β1 / PD-1 protein
[0259] Human TGF-β1 (Acrobiosystems, TG1-H421) or human PD-1 protein was diluted in ELISA coating buffer and added to the ELISA plate for overnight coating at 4°C. The coating buffer was discarded, and the plates were washed three times with 250 μL / well of PBST. The plates were then blocked with 5% BSA for 1 hour at room temperature. Purified PD-1 antibody ADI-54872, 54872-TGF-βRⅡ molecule, TGF-βR2-Fc fusion protein, and a negative control were serially diluted in 1% BSA and added to the blocked ELISA plate. The plates were incubated for 2 hours at room temperature. The plates were washed three times with PBST, and biotin-PD-1 or biotin-anti-TGFβR2 was added to the wells and incubated for 1 hour at room temperature. After washing three times with PBST, Streptavidin-HRP (abcam, ab7403) was added to the wells and incubated at room temperature for half an hour. After washing three times with PBST, ELISA colorimetric solution was added. After standing at room temperature for 3 minutes, ELISA stop solution was added and the absorbance at 450 nm was read.
[0260] In the assay experiment using the above method, the experimental results are shown in Figures 14A-14B , showing that the 54872-TGF-βRⅡ molecule of the present invention co-binds with human TGF-β1 and PD-1 proteins at the ELISA level.
[0261] Example 17: Binding activity of 54872-TGF-βRⅡ molecule to CHO cells overexpressing human PD-1 in the presence of human TGF-β1 protein
[0262] After gradient dilution of the 54872-TGF-βRⅡ molecule, an equal volume of human TGF-β1 protein was added and incubated at room temperature for 30 minutes. The expanded cultured human PD-1 overexpressing CHO cells was adjusted to an appropriate cell density and added to a 96-well flow plate. After centrifugation, the above-incubated sample was added and incubated at 4°C for 30 minutes. The subsequent detection method was the same as in Example 3. In the determination experiment of the above method, the experimental results are shown in Figure 15. The presence of human TGF-β1 protein does not affect the binding activity of the 54872-TGF-βRⅡ molecule of the present invention with the overexpressing human PD-1 CHO cells.
[0263] Example 18: 54872-TGF-βRⅡ molecule blocks the binding activity of PD-L1 to CHO cells overexpressing human PD-1 in the presence of human TGF-β1 protein
[0264] After gradient dilution of the 54872-TGF-βRⅡ molecule, an equal volume of human TGF-β1 protein was added and incubated at room temperature for 30 minutes. The expanded cultured human PD-1 overexpressing CHO cells was adjusted to an appropriate cell density and added to a 96-well flow plate. After centrifugation, the above-incubated sample was added and incubated at 4°C for 30 minutes. The subsequent detection method was the same as in Example 4. In the determination experiment of the above method, the experimental results are shown in Figure 16. The presence of human TGF-β1 protein does not affect the binding activity of the 54872-TGF-βRⅡ molecule of the present invention in blocking PD-L1 and overexpressing human PD-1 CHO cells.
[0265] Example 19: Mixed lymphocyte reaction assay
[0266] Mixed lymphocyte assays were performed using the same method as in Example 7 for the activation of human T lymphocytes using purified PD-1 antibody ADI-54872, 54872-TGF-βRⅡ molecules, TGF-βR2-Fc fusion protein, and negative controls. As shown in Figures 17A-17B , the 54872-TGF-βRⅡ molecules of the present invention can activate T cells to secrete IL-2 and IFN-γ in the MLR assay.
[0267] Example 20: In vivo pharmacodynamic study of 54872-TGF-βRⅡ molecule in B-NDG mice inoculated with A375 and human PBMC
[0268] In this experiment, the anti-tumor activity of the anti-PD-1 antibody of the present invention was determined in a tumor model in which B-NDG mice were co-inoculated with A375 and human PBMC.
[0269] Specifically, an A375 tumor-bearing mouse model was first established by subcutaneously inoculating a mixed A375+PBMC inoculation. When the average tumor volume reached approximately 150 mm3, the mice were grouped and treated with intraperitoneal injections of PBS, 5 mg / kg of Keytruda (Pembrolizumab), 5 mg / kg of ADI-54872 combined with 2.5 mg / kg of TGF-βRII-Fc, and 6 mg / kg of 54872-TGF-βRⅡ (equivalent molar dose to 5 mg / kg of Keytruda). Tumor volume and body weight changes in each group of mice were monitored every 2-3 days for 2 to 3 weeks. The dosage and administration method are shown in Table 7. The results, as shown in Figure 18, demonstrate that the anti-tumor activity of the 54872-TGF-βRⅡ molecule of the present invention is superior to that of an equimolar dose of Keytruda.
[0270] Table 7: Dosing regimen for 54872-TGF-βRⅡ molecule
[0271] Example 21: Pharmacokinetic Evaluation of 54872-TGF-βRⅡ Molecule in Mice
[0272] Eighteen BALB / C mice (half male and half female) were used in the experiment. They were housed under a 12 / 12 hr light / dark cycle, maintained at a temperature of 24 ± 2°C and a humidity of 40-70%, with free access to water and food. They were purchased from Zhejiang Weitong Lihua Experimental Technology Co., Ltd. On the day of the experiment, mice received a single tail vein injection of 54872-TGF-βRⅡ at a dose of 10 mg / kg.
[0273] Blood was collected from the mouse orbital vein at 5 minutes, 0.5 hours, 2 hours, 6 hours, 24 hours, 48 hours, 96 hours, 168 hours, and 336 hours after administration. Whole blood samples were incubated at 2-8°C for 30 minutes, centrifuged at 12,000 rpm for 5 minutes, and serum was collected. The serum was then centrifuged at 12,000 rpm for 5 minutes at 2-8°C and stored at -80°C. The molecular weight of free 54872-TGF-βRII in the serum was determined by ELISA. The results, as shown in Figure 19 and Table 8, indicate that the free 54872-TGF-βRII molecule of the present invention has a half-life of approximately 160 hours in BALB / C mice.
[0274] Table 8: T1 / 2 of 54872-TGF-βRⅡ in mice
[0275] Although the specific embodiments of the present invention have been described in detail, those skilled in the art will understand that various modifications and changes can be made to the details based on all the teachings published, and these changes are all within the scope of protection of the present invention. The entire invention is given by the appended claims and any equivalents thereof.
Claims
1. An antibody or antigen-binding fragment thereof that can specifically bind to PD-1, wherein the antibody or antigen-binding fragment thereof comprises: (i) a heavy chain variable region (VH) comprising the following three complementarity determining regions (CDRs): VH CDR1 of SEQ ID NO: 7 or 13, VH CDR2 of SEQ ID NO: 8, and VH CDR3 of SEQ ID NO: 9; and / or, a light chain variable region (VL) comprising the following three complementarity determining regions (CDRs): VL CDR1 of SEQ ID NO: 10, VL CDR2 of SEQ ID NO: 11 or 14, and VL CDR3 of SEQ ID NO: 12; or, (ii) three CDRs contained in the heavy chain variable region (VH) shown in SEQ ID NO: 1, 3 or 5, and / or three CDRs contained in the light chain variable region (VL) shown in SEQ ID NO: 2, 4 or 6; preferably, the CDRs are identified by the Kabat numbering system, the Chothia numbering system or the IMGT numbering system.
2. The antibody or antigen-binding fragment thereof according to claim 1, wherein The antibody or antigen-binding fragment thereof comprises: (a) a heavy chain variable region (VH) comprising the following three complementarity determining regions (CDRs): VH CDR1 of SEQ ID NO: 7, VH CDR2 of SEQ ID NO: 8, and VH CDR3 of SEQ ID NO: 9; and / or a light chain variable region (VL) comprising the following three complementarity determining regions (CDRs): VL CDR1 of SEQ ID NO: 10, VL CDR2 of SEQ ID NO: 11, and VL CDR3 of SEQ ID NO: 12; or (b) a heavy chain variable region (VH) comprising the following three complementarity determining regions (CDRs): VH CDR1 of SEQ ID NO: 13, VH CDR2 of SEQ ID NO: 8, and VH CDR3 of SEQ ID NO: 9; and / or a light chain variable region (VL) comprising the following three complementarity determining regions (CDRs): VL CDR1 of SEQ ID NO: 10, VL CDR2 of SEQ ID NO: 14, and VL CDR3 of SEQ ID NO:
12.
3. The antibody or antigen-binding fragment thereof according to claim 1 or 2, wherein The antibody or antigen-binding fragment thereof comprises: a heavy chain variable region (VH) comprising the sequence shown in SEQ ID NO: 1, 3 or 5 or a variant thereof; and / or a light chain variable region (VL) comprising the sequence shown in SEQ ID NO: 2, 4 or 6 or a variant thereof; wherein the variant has one or more amino acid substitutions, deletions or additions compared to the sequence from which it is derived (e.g., 1, 2, 3, 4 or 5 amino acid substitutions, deletions or additions), or a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity; preferably, the substitutions are conservative substitutions.
4. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, comprising: (a) a heavy chain variable region (VH) comprising a sequence shown in SEQ ID NO: 1 or 3 or a variant thereof; and / or a light chain variable region (VL) comprising a sequence shown in SEQ ID NO: 2 or 4 or a variant thereof; or (b) a heavy chain variable region (VH) comprising the sequence shown in SEQ ID NO: 5 or a variant thereof; and / or a light chain variable region (VL) comprising the sequence shown in SEQ ID NO: 6 or a variant thereof; in, The variant has one or several amino acid substitutions, deletions or additions (e.g., 1, 2, 3, 4 or 5 amino acid substitutions, deletions or additions) compared to the sequence from which it is derived, or a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity; preferably, the substitutions are conservative substitutions.
5. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, comprising: (1) a VH comprising the sequence shown in SEQ ID NO: 1 and a VL comprising the sequence shown in SEQ ID NO: 2; (2) a VH comprising the sequence shown in SEQ ID NO: 3 and a VL comprising the sequence shown in SEQ ID NO: 4; or, (3) VH comprising the sequence shown in SEQ ID NO: 5 and VL comprising the sequence shown in SEQ ID NO:
6.
6. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, further comprising a constant region derived from a human immunoglobulin; Preferably, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain constant region derived from a human immunoglobulin (e.g., IgG1, IgG2, IgG3, or IgG4), and the light chain of the antibody or antigen-binding fragment thereof comprises a light chain constant region derived from a human immunoglobulin (e.g., κ or λ); Preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain constant region (CH) as shown in SEQ ID NO:
15. and / or a light chain constant region (CL) as shown in SEQ ID NO:
16.
7. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 6, wherein The antigen-binding fragment is selected from Fab, Fab', (Fab')2, Fv, disulfide-linked Fv, scFv, diabody, chimeric antibody, humanized antibody, bispecific antibody or multispecific antibody.
8. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 7, wherein The antibody is an IgG antibody (eg, an IgG1, IgG2, IgG3, or IgG4 antibody).
9. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 8, wherein The antibody or antigen-binding fragment thereof is labeled; preferably, the antibody or antigen-binding fragment thereof is labeled with a detectable label, such as an enzyme (e.g., horseradish peroxidase or alkaline phosphatase), a chemiluminescent reagent (e.g., acridinium ester compounds, luminol and its derivatives, or ruthenium derivatives), a fluorescent dye (e.g., fluorescein or fluorescent protein), a radionuclide, or biotin.
10. A fusion protein comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 9 and another biologically active polypeptide.
11. The fusion protein according to claim 10, wherein The additional biologically active polypeptide is an immunomodulator.
12. The fusion protein according to claim 11, wherein The additional biologically active polypeptide is a TGF-β / TGF-βR pathway inhibitor, such as the TGF-βRII extracellular domain.
13. The fusion protein according to any one of claims 10 to 12, wherein The antibody or antigen-binding fragment thereof and the additional biologically active polypeptide are optionally linked via a peptide linker.
14. The fusion protein according to any one of claims 10 to 13, comprising: comprising the first peptide chain of the light chain of the antibody or antigen-binding fragment thereof; and The present invention comprises the heavy chain of the antibody or antigen-binding fragment thereof and the second peptide chain of the additional biologically active polypeptide.
15. The fusion protein according to claim 14, wherein The first peptide chain comprises the sequence shown in SEQ ID NO: 17, and / or the second peptide chain comprises the sequence shown in SEQ ID NO:
18.
16. A polypeptide construct comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 9, and an immunoglobulin Fc domain; Preferably, the antibody or antigen-binding fragment thereof is an antigen-binding fragment, such as Fab, Fab', (Fab')2, Fv, disulfide-linked Fv, scFv or diabody.
17. The polypeptide construct according to claim 16, wherein The antibody or antigen-binding fragment thereof is a scFv; Preferably, the scFv comprises a disulfide bond; Preferably, the additional biologically active polypeptide is linked to the N-terminus of the scFv, optionally via a peptide linker. The polypeptide construct of claim 17 , comprising the sequence shown in any one of SEQ ID NO: 23 or 24.
19. An isolated nucleic acid molecule encoding the antibody or antigen-binding fragment thereof, or the heavy chain variable region and / or light chain variable region thereof, or encoding the fusion protein of any one of claims 10 to 15, or encoding the polypeptide construct of any one of claims 16 to 18.
20. A vector comprising the nucleic acid molecule according to claim 19; preferably, the vector is a cloning vector or an expression vector.
21. A host cell comprising the nucleic acid molecule of claim 19 or the vector of claim 20.
22. A method for preparing the antibody or antigen-binding fragment thereof according to any one of claims 1 to 9, the fusion protein according to any one of claims 10 to 15, or the polypeptide construct according to any one of claims 16 to 18, comprising culturing the host cell according to claim 21 under conditions that allow protein expression, and recovering the antibody or antigen-binding fragment thereof, fusion protein, or polypeptide construct from the cultured host cell culture.
23. A conjugate comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 9 and a therapeutic agent linked to the antibody or antigen-binding fragment thereof; Preferably, the therapeutic agent is selected from a cytotoxin or a radioisotope.
24. A composition comprising: (1) the antibody or antigen-binding fragment thereof of any one of claims 1-9 or the polypeptide construct of any one of claims 16-18; and (2) an immunomodulator.
25. The composition of claim 24, wherein The immunomodulator is a TGF-β / TGF-βR pathway inhibitor, such as the TGF-βRII extracellular domain.
26. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 9, the fusion protein according to any one of claims 10 to 15, the polypeptide construct according to any one of claims 16 to 18, the conjugate according to claim 23, or the composition according to claim 24 or 25, and a pharmaceutically acceptable carrier and / or excipient; Preferably, the pharmaceutical composition further comprises an additional pharmaceutically active agent; Preferably, the additional pharmaceutically active agent is a drug with anti-tumor activity, such as another immune checkpoint inhibitor, an oncolytic virus, a chemotherapeutic agent, an anti-angiogenic drug, an antimetabolite drug, a tumor-targeting drug or an immunostimulant; Preferably, the additional pharmaceutically active agent is a drug used to treat infection, such as an antiviral agent, an antifungal agent, an antibacterial agent or an immunostimulant; Preferably, the antibody or antigen-binding fragment thereof, the fusion protein, the conjugate or the composition and the additional pharmaceutically active agent are provided as separate components or as components of the same composition.
27. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 9, the fusion protein according to any one of claims 10 to 15, the polypeptide construct according to any one of claims 16 to 18, the conjugate according to claim 23, the composition according to claim 24 or 25, or the pharmaceutical composition according to claim 26 in the preparation of a medicament for: (1) increasing immune cell activity in vitro or in a subject (e.g., human); (2) enhancing an immune response in a subject (e.g., a human); (3) preventing and / or treating tumors in subjects (e.g., humans); (4) preventing and / or treating infection in subjects (e.g., humans); Preferably, the tumor is a tumor with microsatellite instability-high (MSI-H) and / or mismatch repair deficiency (dMMR); Preferably, the tumor is a solid tumor, such as melanoma (e.g., metastatic malignant melanoma), breast cancer, renal cancer (e.g., clear cell carcinoma), prostate cancer, bladder cancer, pancreatic cancer, lung cancer (e.g., non-small cell lung cancer), colon cancer, esophageal cancer, head and neck squamous cell carcinoma, liver cancer, ovarian cancer, cervical cancer, thyroid cancer, glioblastoma, glioma; Preferably, the tumor is a blood tumor, such as lymphoma, leukemia; preferably, the lymphoma is Hodgkin's lymphoma or non-Hodgkin's lymphoma; preferably, the non-Hodgkin's lymphoma is one or more of peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma, Epstein-Barr virus-positive NK / T-cell lymphoma (nasal type) and B-cell non-Hodgkin's lymphoma; Preferably, the infection is selected from viral infection, bacterial infection, fungal infection and parasitic infection; Preferably, the subject is a mammal, such as a human.
28. A method for enhancing an immune response in a subject, and / or preventing and / or treating a tumor or infection; the method comprising: administering to a subject in need thereof an effective amount of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 9, the fusion protein according to any one of claims 10 to 15, the polypeptide construct according to any one of claims 16 to 18, the conjugate according to claim 23, or the composition according to claim 24 or 25, or the pharmaceutical composition according to claim 26; Preferably, the tumor is a tumor with microsatellite instability-high (MSI-H) and / or mismatch repair deficiency (dMMR); Preferably, the tumor is a solid tumor, such as melanoma (e.g., metastatic malignant melanoma), breast cancer, renal cancer (e.g., clear cell carcinoma), prostate cancer, bladder cancer, pancreatic cancer, lung cancer (e.g., non-small cell lung cancer), colon cancer, esophageal cancer, head and neck squamous cell carcinoma, liver cancer, ovarian cancer, cervical cancer, thyroid cancer, glioblastoma, glioma; Preferably, the tumor is a blood tumor, such as lymphoma, leukemia; preferably, the lymphoma is Hodgkin's lymphoma or non-Hodgkin's lymphoma; preferably, the non-Hodgkin's lymphoma is one or more of peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma, Epstein-Barr virus-positive NK / T-cell lymphoma (nasal type) and B-cell non-Hodgkin's lymphoma; Preferably, the infection is selected from viral infection, bacterial infection, fungal infection and parasitic infection; Preferably, the subject is a mammal, such as a human.
29. A kit comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 9; Preferably, the kit comprises the antibody or antigen-binding fragment thereof according to claim 9; Preferably, the kit comprises the antibody or antigen-binding fragment thereof according to any one of claims 1 to 8, and a second antibody that specifically recognizes the antibody or antigen-binding fragment thereof; optionally, the second antibody further comprises a detectable label, such as an enzyme (such as horseradish peroxidase or alkaline phosphatase), a chemiluminescent reagent (such as acridinium ester compounds, luminol and its derivatives, or ruthenium derivatives), a fluorescent dye (such as fluorescein or fluorescent protein), a radionuclide or biotin.
30. A method for detecting the presence or level of PD-1 in a sample, comprising using the antibody or antigen-binding fragment thereof according to any one of claims 1 to 9; Preferably, the method is an immunological assay, such as immunoblotting, enzyme immunoassay (e.g. ELISA), chemiluminescent immunoassay, fluorescent immunoassay or radioimmunoassay; Preferably, the method comprises using the antibody or antigen-binding fragment thereof of claim 9; Preferably, the method comprises using the antibody or antigen-binding fragment thereof according to any one of claims 1 to 8, and the method further comprises detecting the antibody or antigen-binding fragment thereof using a second antibody carrying a detectable label (e.g., an enzyme (e.g., horseradish peroxidase or alkaline phosphatase), a chemiluminescent agent (e.g., an acridinium ester compound, luminol and its derivatives, or a ruthenium derivative), a fluorescent dye (e.g., fluorescein or fluorescent protein), a radionuclide, or biotin); Preferably, the sample is a cell sample (eg, tumor cell) or a tissue sample (eg, tumor tissue) from a subject (eg, a mammal, such as a human).
31. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 9 in the preparation of a detection reagent for detecting the presence or level of PD-1 in a sample; Preferably, the detection reagent detects the presence or level of PD-1 in a sample by the method of claim 30; Preferably, the sample is a cell sample (eg, tumor cells) from a subject (eg, a mammal, such as a human).
Citation Information
Cited By
PD-1 monoclonal antibody and application thereof
CN120518767A
